Composition of Methods (COM)

Composition of Methods (COM): Tool Factory for AI in Health Analytics – Components and Systems – IP Asset Class IV

Curator: Aviva Lev-Ari, PhD, RN

Tool Factory” is a powerful metaphor: It positions COM (now 12 parts) as the manufacturing engine producing executable tools, workflows, and systems (e.g., Parts 10–12: multimodal Execution Infrastructure (EI), validation models, monetization exchanges). This directly counters competitors who are mostly platforms without LPBI’s proprietary “factory” for traceable, hybrid human+AI methods.
“Components and Systems” captures the evolution: Parts 1–9 as foundational components, Parts 10–12 as integrated systems (execution infrastructure, validation, monetization).
“AI in Health Analytics” keeps it domain-focused and ties to Grok’s causal reasoning/medal path—making COM the enabler of YYYs Healthcare Intelligence Hub (HIH/AJAUS).
Impact on Narrative: Reinforces COM as the highest-value class ($xxx.xM+ uplift from Parts 9–12) and the true moat—no competitor has this depth of executable methodology.

LPBI Group’s pioneered the development of Tools called: Composition of Methods (COM).

COM, Tool Factory for AI in Health Analytics – Components and Systems includes the following Methods:

Part 1: The “Curation Methodology” of Scientific Findings

Part 2: SOP on IT aspects of Data management on the Website

https://pharmaceuticalintelligence.com/sop-web-stat/

Part 3: Exploratory Protocols for Multimodal Foundation Model in Healthcare

3.1 Wolfram Code

3.2 Pilot Study with UK-based TOP NLP company, 2021

3.3 Grok 4.1

Part 4: Valuation Model for TEN IP Asset Classes

Slides for Appendices 22, 23

2026 Appendices to Every Slide N = 23 [password protected]

Part 5: Process workflows for six IP Asset Classes

Examples include: a curation article in the Journal, how to create an electronic Table of Content (eTOCs) for an e-Book, a Chapter in an e-Book, e-Proceedings, selection of Biological images and many more

Part 6: Media Gallery of >7,000 Biological Images

Samples by Image type are shown, below

Part 7: Royalties – Data collection on Amazon.com KDP

7.1 At the e-Book Level

7.2 At the e-Series Level

7.3 English Edition, Publishing Period, 6/2013 – 12/2021. Royalties, Book sale and Page downloads, 2013 to Present.

7.4 Spanish Edition, Publishing Period, 12/2022 – 1/2023. Royalties, 2023 to Present.

Slides for Appendices 22, 23

2026 Appendices to Every Slide N = 23 [password protected]

Part 8: IP Asset Class III: Aggregate Calculations of Views for e-Proceedings and Tweet Collections

8.1 Grand Total Views of e-Proceedings & Tweet Collections, 2013 – 2019

[Update for 2020-2025 – PENDING]

8.2 Archive of Real Time PRESS Coverage of Medical, Pharmaceutical and Biotech Conferences, 2013 to Present by (1) Press Reporter Name (2) Event Date(s) (3) Conference Name (4) e-Proceedings URL (5) Tweet Collection URL

[Data Collection – PENDING]

8.3 Marketing Channels for e-Proceedings & Tweet Collections – IP Asset Class III.

Part 9: Scoop.it Platform: Aviva Launched Three Journals since 2013 – a mini vault of N = 888 article titles.

The plan is that in 2026 this Expert culled entries Data Set will be used to create “hybrid curations” aka “Human Guided AI Training Model for Content Creation” thus, Part 9 represents Data repository [data set] for development of a new Method in LPBI Group’s Composition of Methods (COM).

9.1 Journal launched by Aviva Lev-Ari on Cardiovascular and vascular imaging:

5.5K views (2018 data)

9.2 Journal launched by Aviva Lev-Ari on Cardiotoxicity:

693 views (2018 data)

9.3 Journal launched by Aviva Lev-Ari on PHARMACOTHERAPY:

4.3K views (2018 data)

To access these Journal one needs to subscribe on Scoop.it website.

Part 10: Multimodal Methods of Execution Infrastructure (EI) for AI Data Analyses and Exposition of the Analyses Results

It presents the 1st Corporate Application of the Novel Method.
It presents the Published Source(s).

10.1 Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation.

10.2 Method for Data Set Selection for Grok’s LLM & Causal Reasoning – Multimodal Data Set: Text & Images

10.3 Method for Data Set Selection for Grok’s LLM & Causal Reasoning – Multimodal Data Set: Audio, Text & Images

Part 11 – Validation Models for Execution Infrastructures – Library of Modules: Module 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19

11.1 Validation Models for Data Set Selection Methods

11.2 Validation Model for Data Access Sequences prioritized by Executives for knowledge acquisition in Virtual Data Exposition about Acquisition Decision Making

Part 12 – Monetization Schedules for the Hybrid Model, Human & AI – Library of Systems: System 1, System 2, System 3, System 4

SYSTEM #1: Dynamic Intelligence Tokens Exchange [Stock in trade on the Exchange: Journal articles in 4 Domain Knowledge in Healthcare]

SYSTEM #2: Dynamic Image Exchange [Stock in trade on the Exchange: Images (Prior Art)]

SYSTEM #3: Dynamic Podcast Exchange [Stock in trade on the Exchange: Podcasts on Life Sciences Discoveries in the 21st Century]

SYSTEM #4: Dynamic Conference Content Exchange [Stock in trade on the Exchange: e-Proceedings & Tweet Collections Exchange or Dated Speakers & KOLs Quote

Part 13 -Training Data Sets for 15 SMALL Language Models: List of Articles in each Data Set and Methods for Content Augmentation for Transitioning SML to LLM

The output obtained from each of the 15 Subjects Matter from The List of Articles in 1 to 15 data sets is candidate for Content Augmentation.

List of Methods for Content Augmentation

13.1 – Method #1: Updates Output with Autonomous Journal Article Updating System (AJAUS)

13.2 – Method #2: Select additional articles from the List of Categories of Research that a HUMAN Expert MATCHED articles from List with Categories of Research in the List of Categories selected for the articles at hand, see URL, below

13.3 – Method #3: Scoop.it subscription ->>> Search Key words from articles and from Categories. Update the output with AJAUS

13.4 – Method #4: AI Modeling

13.4.1 NLP

13.4.2 Neural Network

13.4.3 Causal Reasoning: Text and Images

13.4.4 Grok Run Benchmark vs Wolfram+ChatGPT plug-in for 2026

13.4.5 Run Benchmark vs Grok’s choices of LLM Actor(s)

13.5 Transition from SLMs to Domain-aware Proprietary LLM – AI in Health

13.5.1 See List of Subjects Matter, below at Part 13.

Details and Itemization

Part 1: The “Curation Methodology” of Scientific Findings

Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences

Curator: Aviva Lev-Ari, PhD, RN

Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

https://pharmaceuticalintelligence.com/2017/05/06/case-studies-of-innovations-in-electronic-scientific-publishing-esp-marketing-econtent-curation-methodology-categories-of-research-functions-interdisciplinary-conceptual-innovations-by-cross-sec/

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

The Methodology of Curation for Scientific Research Findings

https://pharmaceuticalintelligence.com/2014/07/30/the-methodology-of-curation-for-scientific-research-findings/

@PharmaceuticalIntelligence.com – A Case Study on the LEADER in Curation of Scientific Findings

https://pharmaceuticalintelligence.com/2017/06/29/pharmaceuticalintelligence-com-a-case-study-on-the-leader-in-curation-of-scientific-findings/

Curation of Scientific Content @Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

https://pharmaceuticalintelligence.com/2016/08/15/curation-of-scientific-content-leaders-in-pharmaceutical-business-intelligence-lpbi-group-boston/

Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson

https://pharmaceuticalintelligence.com/2014/07/17/scientific-curation-fostering-expert-networks-and-open-innovation-lessons-from-clive-thompson-and-others/

Cardiovascular Diseases and Pharmacological Therapy: Curations by Aviva Lev-Ari, PhD, RN, 2006 – 4/2018

https://pharmaceuticalintelligence.com/2014/04/17/cardiovascular-diseases-and-pharmacological-therapy-curations-by-aviva-lev-ari-phd-rn/

Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA

https://pharmaceuticalintelligence.com/2014/04/07/methodology-for-conference-coverage-using-social-media-2014-massbio-annual-meeting-43-44-2014-royal-sonesta-hotel-cambridge-ma/

Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

https://pharmaceuticalintelligence.com/2013/07/29/cardiovascular-original-research-cases-in-methodology-design-for-content-curation-and-co-curation/

Series A: e-Books on Cardiovascular Diseases

Series A Content Consultant:

Justin D Pearlman, MD, PhD, FACC

VOLUME TWO

Cardiovascular Original Research:

Cases in Methodology Design for Content Co-Curation

The Art of Scientific & Medical Curation

http://www.amazon.com/dp/B018Q5MCN8

Justin D Pearlman, MD, PhD, FACC

Larry H Bernstein, MD, FCAP

and

Aviva Lev-Ari, PhD, RN

4D MRI of atrial septal aneurysm acquired and processed by JDPearlman

Aviva Lev-Ari, PhD, RN

Editor-in-Chief BioMed e-Series of e-Books

Leaders in Pharmaceutical Business Intelligence, Boston

avivalev-ari@alum.berkeley.edu

Cardiovascular Diseases, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation. On Amazon.com since 11/30/2015

http://www.amazon.com/dp/B018Q5MCN8

Submission for Category: Book

Nomination of e-Book, Series A: Cardiovascular Diseases, Volume 2, Cases in Development of Scientific Curation Methodology

2016 Communication Awards Nomination Form Result #9143807

The National Academies of Sciences, Engineering, and Medicine

2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering

Nomination Confirmation

https://pharmaceuticalintelligence.com/biomed-e-books/series-a-e-books-on-cardiovascular-diseases/volume-two-cardiovascular-original-research-cases-in-methodology-design-for-content-co-curation/

Electronic Table of Contents (eTOCs) of Volume Two

Introduction to Volume Two

Part 1: The Methodology of Curation for Scientific Research Findings

1.1 The Methodology Explained

1.1.1 Curation by a Single Curator

1.1.2 Co-Curation by Several Experts, Authors, Writers

1.1.3 Editor’s Curation of an electronic Table of Contents (eTOCs) of an e-Book or a Hardcover Volume

1.2 The Creation Process of a Curation as an Alternative Model for Scientific Publishing

1.3 FIVE steps in the Creation Process of a Curation

1.3.1 CURATION and Co-CURATION of Scientific articles in conjunction with Experts, Authors, Writers critique and synthesis

1.3.2 Assembly of articles into e-Books using ONE of a Kind electronic Table of Contents (eTOCs) architecture

1.3.3 Assembly of e-Books into e-Series

1.3.4 Publishing of e-Series on Amazon.com

1.3.5 Distribution of e-Series to Professional Associations via their Internet website

1.4 Other Alternative Types to the Academic Publishing Model

1.5 Methodology of Curation Applied to Medical Research Findings

1.5.1 The Voice of Content Consultant on The Methodology of Curation

1.5.2 Curation is Uniquely Distinguished by the Historical Exploratory Ties that Bind

Part 2: SOP on IT aspects of Data management on the Website

https://pharmaceuticalintelligence.com/sop-web-stat/

2.1 Project Views extraction

2.2 IT aspects of Web statistics

2.3 Attempt to automate the Classification of all Articles in the journal by type.

Data standardization Phase allowing for automation of the Article Classification remained INCOMPLETE.
Requires advances Talent to pursue an autonomous system architecture allowing for (1) Classification (2) Content Update (3) populate each article with Updates

Part 3: Exploratory Protocols for Multimodal Foundation Model in Healthcare

3.1 Wolfram Code – Example from Genomics, Volume 3 in Spanish Edition

Five comments of note are repeated here from the Original Book and from the New Genre, Genomics Volume 2, PART A & PART C because of their significance:

Genomics, Volume 3 in Spanish Edition

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B0BRD8JXTL $155

Comment #1:

No other book covers the same topics in a single volume

Comment #2:

No other book incorporates 74 e-Proceedings created in real time by the Book’s authors and editors at conferences on Genomics

Comment #3:

No other book incorporates four collections of Tweets representing quotes from speakers at global leading conferences on Genomics

Comment #4:

No other book has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience

Comment #5:

No other book has 326 articles on the topics covered and included in the title of this Book: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

The e-Reader is encouraged to read the Preface, the Introduction and the Epilogue to Genomics Volume 2

Original Volume Two:

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology

On Amazon.com since 12/28/2019

https://www.amazon.com/dp/B08385KF87

AND

the e-Reader is encouraged to continue to Genomics Volume 1

Genomics Orientations for Personalized Medicine

VOLUME ONE

On Amazon.com since 23/11/2015

http://www.amazon.com/dp/B018DHBUO6

NEW GENRE Genomics, Volume Three:

Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS

https://www.amazon.com/dp/B0BRD8JXTL

Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, … de la investigación genómica Book 3) Kindle Edition

by Madison Davis (Author), Aviva Lev-Ari (Editor), Stephen J. Williams (Editor), Marcus W. Feldman (Editor) Format: Kindle Edition

Serie B: Fronteras de la investigación genómica

(3 book series) Kindle Edition

by Larry H. Bernstein (Author) , Stephen J. Williams (Author) , Sudipta Saha (Author) , Ritu Saxena (Author) , Tilda Barliya (Author) , Anamika Sarkar (Author) , Marcus W. Feldman (Author) , Demet Sag (Author) , Prabodh kandala (Author) , Larry H. Bernstein (Author) , Aviva Lev-Ari (Author) , Madison Davis (Author)

https://www.amazon.com/dp/B0BQGZYZVT?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

Appendix to this volume – Wolfram Code

for Hypergraph Plots &
for Tree Diagram Plots

NLP Code writing for 7/8 Parts 1,2,3,4,5,7,8

[No Code for Part 6 in Volume 3]

by

Madison Davis

Code used in production of Hyper-graph Plots at the Book Part Level

Hyper-

graph Plot #1

for 1.1.1 based on

16 articles & on 14 keywords

wordSheet ={

protein,cancer,dna,gene,genes,rna,survival,immune,tumor,research,patients,human,

genome,expression

};

topN = Length[wordSheet];

words = {};

For[i = 1, i <= topN, i++,

words = Append[words, ToString[wordSheet[[i]]]]];

Print[words];

maxN = 3;

broadTerms = {};

words1 = {};

words2 = {};

For[i = 1, i <= topN, i++,If[Length[Position[WordData[], Extract[words, i]]] > 0,

broadTerms = Append[broadTerms, Flatten[Values[WordData[Extract[words, i], “BroaderTerms”]]]];

words1 = Append[words1, Extract[words, i]], words2 = Append[words2, Extract[words, i]]]];

For[i = 1, i <= Length[broadTerms], i++, If[Length[broadTerms[[i]]] > maxN, broadTerms[[i]] = broadTerms[[i]][[1 ;; maxN]]]];

edgeList = {};

edgeList = Append[edgeList,Prepend[words1, “”]] ;

For[i = 1, i <= Length[words1], i++, edgeList = Append[edgeList, Append[broadTerms[[i]], words1[[i]]]]];

ResourceFunction[“HypergraphPlot”][edgeList, VertexSize -> 0.01, VertexLabels -> Automatic, PlotTheme -> “Detailed”, SubsetEdge -> False, SubsetBoundaryScale -> 7, VertexStyle ->

Red,”BaseLayout” -> “RadialEmbedding”,”SubsetEdgeStyle” -> ColorData[100, “ColorList”]]

Hypergraph Plot #2

for 1.1.2

based on

17 articles

& on 12 keywords

wordSheet ={

cancer,mutations,patients,gene,disease,genetic,mutation,data,clinical,tumor,genes,

protein

};

topN = Length[wordSheet];

words = {};

For[i = 1, i <= topN, i++,

words = Append[words, ToString[wordSheet[[i]]]]];

Print[words];

Code used in production of Tree Diagram Plots

Tree Diagram Plot #1

for 1.1.1 based on 16 articles & on 14 keywords

wordSheet ={

protein,cancer,dna,gene,genes,rna,survival,immune,tumor,research,patients,human,

genome,expression

};

topN = Length[wordSheet];

words = {};

For[i = 1, i <= topN, i++,

words = Append[words, ToString[wordSheet[[i]]]]];

Print[words];

maxN = 3;

broadTerms = {};

words1 = {};

words2 = {};

For[i = 1, i <= topN, i++,If[Length[Position[WordData[], Extract[words, i]]] > 0,

broadTerms = Append[broadTerms, Flatten[Values[WordData[Extract[words, i], “BroaderTerms”]]]];

words1 = Append[words1, Extract[words, i]], words2 = Append[words2, Extract[words, i]]]];

For[i = 1, i <= Length[broadTerms], i++, If[Length[broadTerms[[i]]] > maxN, broadTerms[[i]] = broadTerms[[i]][[1 ;; maxN]]]];

edgeList = {};

For[i = 1 , i <= Length[broadTerms], i++, edgeList = Append[edgeList, broadTerms[[i]]]];

For[i = 1 , i <= Length[broadTerms], i++, For[j = 1, j <= Length[edgeList[[i]]], j++, edgeList[[i]][[j]] = words1[[i]] -> edgeList[[i]][[j]]]];

For[i = 1 , i <= Length[words1], i++, edgeList = Append[edgeList, {“Chapter 1.1.1” -> words1[[i]]}]];

TreePlot[Flatten[edgeList], VertexSize -> 0.1, VertexLabels -> Automatic]

Tree Diagram Plot #2

for 1.1.2

based on 17 articles & on 12 keywords

wordSheet ={

cancer,mutations,patients,gene,disease,genetic,mutation,data,clinical,tumor,genes,

protein

};

topN = Length[wordSheet];

words = {};

For[i = 1, i <= topN, i++,

words = Append[words, ToString[wordSheet[[i]]]]];

Print[words];

3.2 Pilot Study with UK-based TOP NLP company, 2021

3.3 Grok 4.1

Exploratory Protocol for Comparison of NLP to LLM on Same Oncology Slice

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD, KOL on Cancer & Oncology

https://pharmaceuticalintelligence.com/2025/12/08/exploratory-protocol-for-comparison-of-nlp-to-llm-on-same-oncology-slice/

2025 Grok 4.1 Causal Reasoning & Multimodal on Identical Proprietary Oncology Corpus: From 673 to 5,312 Novel Biomedical Relationships: A Direct Head-to-Head Comparison with 2021 Static NLP – NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus Transforms Grok into the “Health Go-to Oracle”

Authors:

Stephen J. Williams, PhD (Chief Scientific Officer, LPBI Group)
Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief Journal and BioMed e-Series, LPBI Group)
Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2025/12/15/2025-grok-4-1-causal-reasoning-multimodal-on-identical-proprietary-oncology-corpus-from-673-to-5312-novel-biomedical-relationships-a-direct-head-to-head-comparison-with-2021-static-nlp-new-foun/

Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/2025/11/15/authentic-relevance-of-lpbi-groups-portfolio-of-ip-as-proprietary-training-data-corpus-for-ai-initiatives-at-big-pharma/

Generative AI Providers: Open Source and Closed source, @Google’s JAX AI stack versus @xAI @Grok

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2025/12/03/generative-ai-providers-open-source-and-closed-source-googles-jax-ai-stack-versus-xai-and-grok/

Part 4: Valuation Model for TEN IP Asset Classes

Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2025/12/08/valuation-models-per-ten-digital-ip-asset-classes-in-lpbi-groups-portfolio-of-ip/

Part 5: Process Workflows for Six IP Asset Classes

CONTENT CREATION PROCESS WORKFLOW DIAGRAMS for Five of the TEN LPBI IP ASSET CLASSES

LPBI’s value chain from data to knowledge for the Knowledge workers in the Life Sciences and for the Consumers of Medical and Healthcare-related contents

These are the processes that LPBI’s team of experts employ to convert information into valuable knowledge

Composition of Methods: Process Workflows

IP Asset Class I: Journal Articles

New Number Updates 12/27/2025

Views 2,522,657; Visitors 1,560,952; Posts 6,275;

tags: >10,xxx; Comments: >7,4yy

[Old Numbers: 11/23/2020]

IP Asset Class II: e-Books in Medicine

Updated on 12/27/2025

English Edition: 18 Volumes in 17 Books + Bundles: 5 e-Series:

Series A, 6 volumes

Series B, 2 volumes

Series C, 2 volumes

Series D, 3 volumes: Volume 1, Volume 2 & 3, Volume 4

Series E, 4 volumes

Spanish Edition: 19 Volumes in 19 Books + Bundles: 5 e-Series:

Series A, 6 volumes

Series B, 3 volumes

Series C, 2 volumes

Series D, 4 volumes, Volume 1,2,3,4

Series E, 4 volumes

Old Data: 11/13/2020

Asset Class III: e-Proceedings of Biotech & Medical Conferences & Tweet Collections

IP Asset Class IV: Portal Launch Method

A Case in Point: Coronavirus Portal – a case of portal launch in 8 hours, 3/14/2020

IP Asset Class X: e-Voices Audio Podcasts –

A Library of Scientists Biographies

IP Asset Class V: Media Gallery of >7,000 Biological Images

The entire Media Gallery needs to be classified into Categories of Images, i.e., Type of Images

Classification Methods for Biological Images by Type, see examples, below, Part 6

Type 1: Analytics

Type 2: Word Clouds: AI in Medical Text Analysis with NLP

Type 3: Biological images

Type 4: People of Note

Type 5: Cover Pages of Books Published by LPBI Group.

Type 6: Genomics Research (mRNA) and Drug Activity

Part 6: Image Type: Classification of Items in the Media Gallery of >7,000 Biological Images

IP Asset Class V: Biological Images – Image Type Examples

The entire Media Gallery needs to be classified into types. Below, we feature 6 types by examples:

Type 1: Analytics
Type 2: Word Clouds: AI in Medical Text Analysis with NLP
Type 3: Biological images
Type 4: People of Note
Type 5: Cover Pages of Books Published by LPBI Group.
Type 6: Genomics Research (mRNA) and Drug Activity

Type 1: Analytics

[Graphs and Text]

Number of drug approvals by regulatory agency. Source: Yan Y, Guo X, Li Z, Shi W, Long M, Yue X, Kong F, Zhao Z. New Drug Approvals in China: An International Comparative Analysis, 2019-2023. Drug Des Devel Ther. 2025 Apr 3;19:2629-2639. doi: 10.2147/DDDT.S514132.

Type 2: Word Clouds: AI in Medical Text Analysis: NLP statistical algorithm

[Text & Image]

WordCloud Produced by Arav Gandhi

Imaged uploaded to Gallery on December 13, 2022

Type 3: Biological images

[Image and Text]

Type 4: People of Note

Professor Allan Pred, Advisor of Aviva Lev-Ari, PhD, RN at University of California, Berkeley,

9/1978 – 12/1983, Berkeley, California.

Aviva Lev-Ari, 9/1978, Picture on StudentID at UC, Berkeley, 1st year in doctoral program. Dissertation filed with Graduated Division, 12/1983.

Degree earned: UC, Berkeley, PhD’83.

Dr. Zelig Eshhar, A Founding Father of CAR-T cell Immunotherapy passed away on 7/4/2025

https://pharmaceuticalintelligence.com/2025/07/08/dr-zelig-eshhar-a-founding-father-of-car-t-passed-away-on-7-4-2025/

Type 5: Cover Pages of Books Published by LPBI Group [N = 48]

[Image and Text]

Type 6: Genomics Research (mRNA) and Drug Activity

[Image and Text]

Fig. 2. Chronic exposure to degraders induces MDR1 expression and drug efflux activity.

(A) ABCB1 mRNA levels in parental and degrader-resistant cell lines as determined by qRT-PCR. Data are means ± SD of three independent experiments. ***P ≤ 0.001 by Student’s t test.

(B) Immunoblot analysis of MDR1 protein levels in parental and degrader-resistant cell lines. Blots are representative of three independent experiments. (C to E) Immunofluorescence (“IF”) microscopy of MDR1 protein levels in A1847 dBET6-R

(C), SUM159 MZ1-R

(D), and Thal-R A1847 cells

(E) relative to parental cells. Nuclear staining by DAPI. Images are representative of three independent experiments. Scale bars, 100 μm.

(F) Drug efflux activity in A1847 dBET6-R, SUM159 MZ1-R, and Thal-R A1847 cells relative to parental cells (Par.) using rhodamine 123 efflux assays. Bars are means ± SD of three independent experiments. ***P ≤ 0.001 by Student’s t test.

(G) Intracellular dBET6 levels in parental or dBET-R A1847 cells transfected with a CRBN sensor and treated with increasing concentrations of dBET6. Intracellular dBET6 levels measured using the CRBN NanoBRET target engagement assay. Data were analyzed as % of DMSO control, presented as means ± SD of three independent assays. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 by Student’s t test. (H and I) FISH analysis of representative drug-sensitive parental and drug-resistant A1847

(H) and SUM159

(I) cells using ABCB1 and control XCE 7 centromere probes. Images of interphase nuclei were captured with a Metasystems Metafer microscope workstation, and the raw images were extracted and processed to depict ABCB1 signals in magenta, centromere 7 signals in cyan, and DAPI-stained nuclei in blue. (J and K) CpG methylation status of the ABCB1 downstream promoter (coordinates: chr7.87,600,166-87,601,336) by bisulfite amplicon sequencing in parent and degrader-resistant A1847

(J) and SUM159

(K) cells. Images depict the averaged percentage of methylation for each region of the promoter, where methylation status is depicted by color as follows: red, methylated; blue, unmethylated. Schematic of the ABCB1 gene with the location of individual CpG sites is shown. Graphs are representative of three independent experiments. (L and M) Immunoblot analysis of MDR1 protein levels after short-term exposure [for hours (h) or days (d) as indicated] to BET protein degraders dBET6 or MZ1 (100 nM) in A1847

(L) and SUM159

(M) cells, respectively. Blots are representative of three independent experiments. (N to P) Immunoblot analysis of MDR1 protein levels in A1847 and SUM159 cells after long-term exposure (7 to 30 days) to BET protein degraders dBET6

(N), Thal SNS 032

(O), or MZ1

(P), each at 500 nM. Blots are representative of three independent experiments. (Q and R) Immunoblot analysis of MDR1 protein levels in degrader-resistant A1847

(Q) and SUM159

(R) cells after PROTAC removal for 2 or 7 days. Blots are representative of three independent experiments. Related data are in fig. S2 and data file S2.

Part 7: Royalties – Data collection on Amazon.com KDP

English Edition, Publishing Period, 6/2013 – 12/2021.

Royalties, 2013 to Present.

Spanish Edition, Publishing Period, 12/2022 – 1/2023.

Royalties, 2023 to Present.

7.1 Totals: Two Editions, All page downloads – Data for 12/27/2025

2013-2022: English Edition

136,940

2023: English & Spanish Edition

137,128

2024:English & Spanish Edition

146,387

2025 till 9/2025: English & Spanish Edition

150,278

TOTALS: on 12/26/2025

151,761

7.2 At the e-Book Level

[Update is PENDING]

Royalties based on Page Read (KENP) – Royalties Extract by e-Book in Spanish Edition – Page Extract Image

Date	Title	Author Name	ASIN	Market place	Kindle Edition Normalized Page (KENP) Read
2023-04-05	Lo último en metodologías genómicas para agentes terapéuticos: edición génica, SMP y bioinformática, simulaciones y la ontología del genoma PAGES READ = 46	Larry H. Bernstein	B0BQH14CSF	Amazon.es	46
2023-04-05	Orientaciones genómicas para la medicina personalizada Orientaciones genómicas para la medicina personalizada PAGES READ = 33	Larry H. Bernstein	B0BQGZRQ2C	Amazon.es	33
2023-04-05	Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology PAGES READ = 69	Madison Davis	B0BRD8JXTL	Amazon.es	69
2023-04-03	Cardiología intervencionista para el diagnóstico de enfermedades y cirugía cardíaca para el tratamiento de afecciones PAGES READ = 33	Justin D. Pearlman	B0BPRDLFNH	Amazon.com.mx	33

7.3 At the e-Series Level

[Update is PENDING]

e-Series	Actual
	2013 – 2022
TOTAL Page downloads English Edition 2013-2022	136,940
Series A	37,818
Series B	12,282
Series C	32,186
Series D	36,478
Series E	18,176

7.4 Royalties paid for Book Sale and Page downloads in USD, GBP, EUR, 5/2013 to 2/2023

[Data update – PENDING]

Date	KENP Read 5/2013 to 2/2023	Royalty (USD)	Royalty (GBP)	Royalty (EUR)
e-Book Page Downloads	138,896	Sale of an e-Book of $75 yield $26 Royalty (35%)
February 2023	572	1.35	0.00	0.13
January 2023	1198	0.01	0.00	3.02
December 2022	1575	0.49	1.60	0.00
November 2022	106	0.04	0.00	0.00
October 2022	340	0.45	0.00	0.00
September 2022	1755	6.06	0.00	0.20
August 2022	645	2.75	0.00	0.00
July 2022	1121	3.89	0.65	0.00
June 2022	296	1.36	0.00	0.00
May 2022	86	0.20	0.00	0.00
April 2022	55	0.11	0.00	0.00
March 2022	278	0.54	0.00	0.00
February 2022	96	0.27	0.00	0.00
January 2022	1709	3.03	1.50	0.00
December 2021	55	0.00	0.00	0.23
November 2021	339	1.54	0.00	0.00
October 2021	142	0.29	0.00	0.00
September 2021	141	0.28	0.00	0.00
August 2021	81	0.04	0.18	0.01
July 2021	114	0.46	0.01	0.01
June 2021	93	0.00	0.01	0.06
May 2021	731	0.26	0.11	0.00
April 2021	114	0.51	0.00	0.00
March 2021	1370	26.33	0.02	0.00
February 2021	95	0.00	0.03	0.06
January 2021	2049	8.63	0.00	0.00
December 2020	184	35.32	0.02	0.17
November 2020	221	0.00	0.00	0.03
October 2020	487	1.71	0.00	0.00
September 2020	1301	5.93	0.02	0.00
August 2020	2258	32.62	0.00	1.11
July 2020	468	0.66	0.00	0.15
June 2020	257	1.10	0.00	0.01
May 2020	4848	39.84	0.00	0.04
April 2020	275	0.81	0.04	0.12
March 2020	554	28.81	0.00	0.00
February 2020	1242	26.54	0.45	0.00
January 2020	347	36.43	0.00	0.00
December 2019	3148	14.59	0.02	0.00
November 2019	495	0.53	0.00	0.00
October 2019	4777	13.88	0.00	6.22
September 2019	883	1.44	1.28	0.00
August 2019	937	30.03	0.00	0.00
July 2019	82	0.17	0.00	0.00
June 2019	1542	6.42	0.00	0.14
May 2019	517	0.90	0.96	0.00
April 2019	818	27.10	0.00	0.00
March 2019	2025	4.15	0.26	0.00
February 2019	148	0.30	0.00	0.00
January 2019	1043	27.18	0.37	0.00
December 2018	1792	7.14	0.91	0.19
November 2018	1361	0.02	0.00	6.86
October 2018	6733	14.70	0.06	0.00
September 2018	129	0.23	0.00	0.10
August 2018	57	0.20	0.00	0.00
July 2018	206	0.80	0.00	0.00
June 2018	103	0.42	0.00	0.03
May 2018	215	52.57	0.00	0.00
April 2018	681	29.13	0.03	0.09
March 2018	2961	0.00	0.00	0.00
February 2018	1616	3.03	0.00	0.00
January 2018	5684	7.15	0.71	9.17
December 2017	1016	0.00	0.02	1.76
November 2017	4742	18.13	0.13	0.92
October 2017	4447	5.34	11.38	0.08
September 2017	4911	7.33	0.50	0.11
August 2017	906	3.80	0.00	0.00
July 2017	246	0.13	0.00	0.00
June 2017	510	2.10	0.00	0.00
May 2017	162	0.70	0.00	0.00
April 2017	290	0.71	0.00	0.00
March 2017	557	26.26	0.01	2.51
February 2017	188	26.35	0.02	0.80
January 2017	2332	30.68	0.00	0.00
December 2016	1734	8.13	0.00	0.14
November 2016	835	4.49	0.00	0.00
October 2016	3725	23.65	0.16	0.00
September 2016	40	52.69	0.00	0.00
August 2016	10613	0.19	0.00	0.00
July 2016	3849	7.52	0.00	0.00
June 2016	2968	13.56	0.00	20.37
May 2016	3091	0.54	0.19	0.00
April 2016	1436	6.83	0.00	0.00
March 2016	5728	26.90	0.00	9.99
February 2016	2677	6.05	0.00	0.00
January 2016	5040	6.00	0.07	7.19
December 2015	2216	35.73	0.00	0.00
November 2015	4129	20.21	0.00	0.05
October 2015	144	0.22	0.00	0.00
September 2015	1528	5.48	0.01	1.84
August 2015	3284	9.91	0.41	5.66
July 2015 Pay-per-view launched by Amazon.com	1	0.00	0.00	0.00
June 2015	N/A	0.00	0.00	0.00
May 2015	N/A	0.00	0.00	0.00
April 2015	N/A	0.00	0.00	0.00
March 2015	N/A	2.67	0.00	0.00
February 2015	N/A	0.00	0.00	0.00
January 2015	N/A	0.00	0.00	0.00
December 2014	N/A	0.00	0.00	0.00
November 2014	N/A	0.00	0.00	0.00
October 2014	N/A	0.00	0.00	0.00
September 2014	N/A	1.52	0.00	0.00
August 2014	N/A	1.54	0.00	0.00
July 2014	N/A	1.81	0.00	0.00
June 2014	N/A	0.00	0.00	0.00
May 2014	N/A	0.00	0.00	0.00
April 2014	N/A	0.00	0.00	0.00
March 2014	N/A	0.00	0.00	0.00
February 2014	N/A	0.00	0.00	0.00
January 2014	N/A	1.93	0.00	0.00
December 2013	N/A	0.00	0.00	0.00
November 2013	N/A	26.92	0.00	0.00
October 2013	N/A	0.00	0.00	0.00
September 2013	N/A	2.42	0.00	0.00
August 2013	N/A	0.00	0.00	0.00
July 2013	N/A	0.00	0.00	0.00
June 2013	N/A	26.25	0.00	0.00
May 2013	N/A	0.00	0.00	0.00

Page download Royalties paid in INR, CAD, BRL, MXN,

5/2013 to 2/2023

Spanish Edition Published on 12/2022 & 1/2023

[Data updated – Pending]

Date	Royalty (INR)	Royalty (CAD)	Royalty (BRL) Brazil	Royalty (MXN)

February 2023	17.04	0.00	0.17	0.00
January 2023	3.98	0.00	0.09	7.34
December 2022	65.44	0.00	1.42	1.52
November 2022	8.27	0.00	0.00	0.00
October 2022	2.65	0.82	0.00	0.00
September 2022	35.68	0.00	0.00	0.00
August 2022	0.00	0.00	0.00	0.00
July 2022	0.00	0.00	0.00	0.00
June 2022	0.00	0.00	0.00	0.00
May 2022	0.17	0.16	0.00	0.00
April 2022	2.48	0.00	0.00	0.00
March 2022	12.73	0.00	0.00	0.00
February 2022	0.00	0.00	0.00	2.62
January 2022	0.00	0.00	4.21	0.00
December 2021	0.00	0.00	0.00	0.00
November 2021	1.37	0.00	0.00	0.00
October 2021	1.97	0.22	0.00	0.00
September 2021	0.00	0.31	0.00	0.00
August 2021	0.49	0.00	0.00	0.21
July 2021	0.00	0.00	0.00	0.00
June 2021	5.52	0.00	0.00	0.00
May 2021	53.77	0.00	0.00	0.00
April 2021	0.00	0.00	0.00	0.00
March 2021	114.54	0.00	0.00	0.00
February 2021	0.00	0.00	0.00	0.00
January 2021	0.00	0.00	0.00	0.00
December 2020	4.41	0.00	0.00	0.00
November 2020	18.86	0.00	0.00	0.00
October 2020	4.61	0.00	0.00	0.00
September 2020	0.00	0.00	0.00	0.00
August 2020	0.00	0.00	0.00	1.01
July 2020	3.29	0.00	0.00	0.00
June 2020	1.06	0.00	0.00	0.00
May 2020	12.18	0.00	0.00	0.00
April 2020	0.25	0.00	0.00	0.00
March 2020	0.00	0.00	0.00	0.00
February 2020	17.42	0.00	0.06	0.00
January 2020	1.80	0.00	0.00	0.00
December 2019	1.18	0.00	0.00	0.00
November 2019	11.40	0.00	0.00	0.00
October 2019	42.11	0.00	0.02	0.00
September 2019	0.00	0.00	0.00	0.00
August 2019	6.48	0.00	0.00	0.00
July 2019	3.76	0.00	0.00	0.00
June 2019	4.06	0.00	0.15	5.25
May 2019	0.91	0.00	0.00	2.09
April 2019	57.62	0.00	0.00	0.00
March 2019	18.68	0.00	0.00	0.00
February 2019	0.28	0.00	0.77	0.00
January 2019	61.42	0.01	0.00	0.00
December 2018	0.09	0.00	0.00	0.41
November 2018	2.13	0.00	0.00	0.00
October 2018	346.45	0.00	0.00	0.00
September 2018	4.56	0.00	0.00	0.00
August 2018	0.00	0.00	0.00	0.97
July 2018	2.53	0.00	0.00	0.00
June 2018	0.00	0.00	0.00	0.00
May 2018	17.59	0.00	0.00	0.00
April 2018	0.44	0.00	0.00	0.00
March 2018	214.97	0.00	0.00	0.00
February 2018	0.00	4.42	0.00	0.00
January 2018	73.97	0.05	0.00	0.00
December 2017	0.00	0.00	0.06	0.00
November 2017	47.36	0.00	0.68	0.00
October 2017	0.00	0.00	0.00	0.00
September 2017	7.06	0.00	0.00	0.00
August 2017	0.00	0.00	0.00	0.00
July 2017	16.87	0.00	0.00	0.00
June 2017	0.99	0.00	0.00	0.00
May 2017	0.00	0.00	0.00	0.00
April 2017	0.00	0.00	0.00	0.00
March 2017	0.09	0.00	0.00	0.00
February 2017	0.00	0.00	0.00	0.00
January 2017	18.19	0.00	0.00	0.00
December 2016	16.74	0.00	0.00	0.00
November 2016	0.00	0.00	0.00	0.00
October 2016	341.36	0.00	0.00	1.38
September 2016	0.10	0.00	0.00	0.00
August 2016	0.00	0.00	0.00	3.73
July 2016	238.37	0.03	0.00	0.00
June 2016	22.91	0.00	0.00	0.00
May 2016	294.14	0.12	0.00	0.00
April 2016	1683.74	0.00	0.00	0.00
March 2016	9.36	11.75	0.00	0.00
February 2016	4.26	0.03	0.00	0.00
January 2016	2.92	0.00	0.00	0.00
December 2015	16.12	0.00	0.00	0.00
November 2015	1.29	0.00	0.00	0.00
October 2015	31.00	0.00	0.00	0.00
September 2015 – Pay-per-View Launched by Amazon	0.99	0.00	0.73	0.00
June 2013 to August 2015: Book Sale data on another Table [Excel file]	0.00	0.00	0.00	0.00
July 2015	0.00	0.00	0.00	0.00
June 2015	0.00	0.00	0.00	0.00
May 2015	0.00	0.00	0.00	0.00
April 2015	0.00	0.00	0.00	0.00
March 2015	0.00	0.00	0.00	0.00
February 2015	0.00	0.00	0.00	0.00
January 2015	0.00	0.00	0.00	0.00
December 2014	0.00	0.00	0.00	0.00
November 2014	0.00	0.00	0.00	0.00
October 2014	0.00	0.00	0.00	0.00
September 2014	0.00	0.00	0.00	0.00
August 2014	0.00	0.00	0.00	0.00
July 2014	0.00	0.00	0.00	0.00
June 2014	0.00	0.00	0.00	0.00
May 2014	0.00	0.00	0.00	0.00
April 2014	0.00	0.00	0.00	0.00
March 2014	0.00	0.00	0.00	0.00
February 2014	0.00	0.00	0.00	0.00
January 2014	0.00	0.00	0.00	0.00
December 2013	0.00	0.00	0.00	0.00
November 2013	0.00	0.00	0.00	0.00
October 2013	0.00	0.00	0.00	0.00
September 2013	0.00	0.00	0.00	0.00
August 2013	0.00	0.00	0.00	0.00
July 2013	0.00	0.00	0.00	0.00
June 2013	0.00	0.00	0.00	0.00
May 2013	0.00	0.00	0.00	0.00

Part 8: IP Asset Class III: Aggregate Calculations of Views for e-Proceedings and Tweet Collections

To See all Conferences covered by Aviva

List of Medical, Pharmaceutical and BioTech Conferences Covered by Aviva Lev-Ari, PhD, RN, 2013 to Present: Total # and Total Views

and

To See all Conferences covered by Dr. Williams

List of Medical, Pharmaceutical and BioTech Conferences Covered by Stephen J. Williams, PhD, 2015 to Present: Total # and Total Views

To See all e-Proceedings and all Tweet Collections

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

8.1 Grand Total Views of e-Proceedings & Tweet Collections, 2013 – 2019

[Update for 2020-2025 – PENDING]

YEAR

Tweed Collections

# of Views

$

Grand Total

$

Potential Revenues from DOWNLOADS

e-Proceedings and Tweet Collections at $100 per item

Grand Total Views

2013 – 2019

Total

Aviva Lev-Ari & Stephen J Williams

1,090

109,000

1,368,500

13,685

YEAR

# Events Covered generating e-Proceeding (some events covered by iPhone Tweeting Pictures and Comments, only) Event counted as 1 even if it generated multiple article entires

e-Proceedings # of Views

$

Tweets Collections (TC) generated

# of Items

2016: Twitter used in Conference coverage

Total

2013 – 2019

Aviva Lev-Ari

&

Stephen J Williams

60 12,595

1,259,500

36

8.2 Archive of Real Time PRESS Coverage of Medical, Pharmaceutical and Biotech Conferences, 2013 to Present by (1) Press Reporter Name (2) Event Date(s) (3) Conference Name (4) e-Proceedings URL (5) Tweet Collection URL

SOURCES

https://pharmaceuticalintelligence.com/press-coverage/

https://pharmaceuticalintelligence.com/press-coverage/part-two-list-of-biotech-conferences-2013-to-present/

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

[Data Collection – PENDING]

1 Press Reporter Name	2 Event Date(s)	3 Conference Name	4 e-Proceedings URL	5 Tweet Collection URL
Aviva Lev-Ari, PhD, RN	00/00/2025

Press

Reporter

Dates

Conference Name

e-Proceedings URL

Tweet

Collection

URL

Stephen J. Williams, PhD

00/00/2025

8.3 Channels for e-Marketing of Biotech Conferences: IP Asset Class III: e-Proceedings & Tweet Collections

Our Journal http://pharmaceuticalintelligence.com

On 3/3/2020

1,723,362 e-Readers
5,742 Articles
694 Research Categories – Journal Ontology
10,154 Tags
7,379 Global scientists comments

On 12/29/2025

2,523,172 e-Readers
1,561,284 Visitors
6,275 Articles
757 Research Categories – Journal Ontology
Tags [Update – PENDING]
Global scientists comments [Update – PENDING]

On 3/3/2020

Aviva’s +7,164 BIOTECH Followers on LinkedIn

On 12/29/2025

Aviva’s 8,793 connections on LinkedIn
Aviva’s 9,261 followers on LinkedIn

http://www.linkedin.com/in/avivalevari

Aviva is a Member of +80 LinkedIn Groups in Biotech related fields

https://www.linkedin.com/groups/my-groups

LPBI Group’s FaceBook Page

http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence

We co-Market and Co-Promote Events

Venture Summit | West – “Where Innovation Meets Capital”, March 23rd & 24th 2020, Santa Clara Convention Center, Silicon Valley

Preliminary Agenda Available and Exclusive Discount to attend Understanding CRISPR: Mechanisms to Applications Symposium in Boston (September 19, 2016)

LPBI Group’s X.com [ex-Twitter] Account

http://twitter.com/pharma_BI

LPBI Group’s Founder’s Account on X.com [ex-Twitter]

https://x.com/AVIVA1950

Aviva is a LinkedIn (LI) Group Launcher and Manager of Three LI Groups

Cardiovascular Biotech & Pharma UK & US Networking Group

918 members (1/2019)

1,291 members (12/2025)

Innovation in Israel

197 members (1/2019)

388 member (12/29/2025)

Leaders in Pharmaceutical Business Intelligence

342 members (1/2019)

367 members (12/2025) – New Members are following the Company’s Page, below

LPBI Group’s Company’s Page on LinkedIn –
LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE GROUP, LLC, DOING BUSINESS AS LPBI GROUP, NEWTON, MA

639 followers

https://www.linkedin.com/company/9325543?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A9325543%2Cidx%3A1-1-1%2CtarId%3A1439226813927%2Ctas%3ALeaders%20in%20Pharmaceutica

Getting from LinkedIn the Identity of the Followers of LPBI Group’s Page requires an upgrade to the current Premium Account in place [Not pursued, yet].

The Global Geographies of LPBI Group’s Company’s Page on LinedIn.com

Greater Boston 39 (6.1%)
New York City Metropolitan Area 26 (4.1%)
Los Angeles Metropolitan Area 11 (1.7%)
San Francisco Bay Area 11 (1.7%)
Greater Chicago Area 11 (1.7%)
Greater Delhi Area, India 10 (1.6%)
London Area, United Kingdom, United Kingdom 10 (1.6%)
Greater Paris Metropolitan Region, France 10 (1.6%)
Greater Ahmedabad Area, India 10 (1.6%)
Mumbai Metropolitan Region, India 10 (1.6%)
Dallas-Fort Worth Metroplex 9 (1.4%)
Cairo, Egypt 9 (1.4%)
Greater Bengaluru Area, India 8 (1.3%)
Raleigh-Durham-Chapel Hill Area 7 (1.1%)
Miami-Fort Lauderdale Area 7 (1.1%)
Greater Philadelphia 7 (1.1%)
Washington DC-Baltimore Area 6 (< 1%)
Greater Hyderabad Area, India 6 (< 1%)
Shanghai, China 6 (< 1%)
Greater Indore Area, India 6 (< 1%)
Greater Houston 5 (< 1%)
Greater Tampa Bay Area 5 (< 1%)
San Diego Metropolitan Area 5 (< 1%)
Lahore, Pakistan 5 (< 1%)
Pune/Pimpri-Chinchwad Area, India 5 (< 1%)
Greater Istanbul, Türkiye 5 (< 1%)
Greater Chennai Area, India 5 (< 1%)
Karāchi, Pakistan 4 (< 1%)
Greater Dublin, Ireland 4 (< 1%)
Greater Lucknow Area, India 4 (< 1%)
Greater Kolkata Area, India 4 (< 1%)
Dhaka, Bangladesh 4 (< 1%)
Atlanta Metropolitan Area 4 (< 1%)
Kansas City Metropolitan Area 3 (< 1%)
Greater Ancona Metropolitan Area, Italy 3 (< 1%)
Greater São Paulo Area, Brazil 3 (< 1%)
Greater Seattle Area 3 (< 1%)
Greater Vancouver Metropolitan Area, Canada 3 (< 1%)
Mexico City Metropolitan Area, Mexico 3 (< 1%)
Salt Lake City Metropolitan Area 3 (< 1%)
Giza, Egypt 3 (< 1%)
Greater Montreal Metropolitan Area, Canada 3 (< 1%)
Tehran, Iran 3 (< 1%)
Hanoi Capital Region, Vietnam 3 (< 1%)
Greater Milan Metropolitan Area, Italy 3 (< 1%)
Greater Tucson Area 2 (< 1%)
Tbilisi, Georgia 2 (< 1%)
Greater Phoenix Area 2 (< 1%
Lisbon Metropolitan Area, Portugal 2 (< 1%)
Grand Rapids Metropolitan Area 2 (< 1%)
Porto Metropolitan Area, Portugal 2 (< 1%)
Rhein-Neckar Metropolitan Region, Germany 2 (< 1%)
Greater Minneapolis-St. Paul Area 2 (< 1%)
Greater Orlando 2 (< 1%)
Lausanne Metropolitan Area, Switzerland 2 (< 1%)
Hong Kong SAR, China 2 (< 1%)
Hanover 2 (< 1%)
Bogotá D.C. Metropolitan Area, Colombia 2 (< 1%)
Greater Turin Metropolitan Area, Italy 2 (< 1%)
Greater Izmir, Türkiye 2 (< 1%)
Greater Madrid Metropolitan Area, Spain 2 (< 1%)
Detroit Metropolitan Area 2 (< 1%)
Jakarta Metropolitan Area, Indonesia 2 (< 1%)
Greater Salisbury Area 2 (< 1%)
Greater Vadodara Area, India 2 (< 1%)
Greater Lyon Area, France 2 (< 1%)
Charlotte Metro 2 (< 1%)
Greater Madison Area 2 (< 1%)
Greater Lexington Area 2 (< 1%)
Greater Nagpur Area, India 2 (< 1%)
London, Canada Metropolitan Area, Canada 2 (< 1%)
Greater Alor Setar, Malaysia 2 (< 1%)
Greater Toronto Area, Canada, Canada 2 (< 1%)
Colombo, Sri Lanka 2 (< 1%)
Beijing, China 1 (< 1%)
Limerick Metropolitan Area, Ireland 1 (< 1%)
Nanchang, China 1 (< 1%)
Lipa, Philippines 1 (< 1%)
Changzhou-Wuxi-Suzhou Metropolitan Area, China 1 (< 1%)
Metro Davao, Philippines 1 (< 1%)
Guangzhou-Foshan Metropolitan Area, China 1 (< 1%)
Greater Sheffield Area, United Kingdom 1 (< 1%)
Panipat, India 1 (< 1%)
Greater Grand Forks Area 1 (< 1%)
Belgaum, India 1 (< 1%)
Greater Southampton Area, United Kingdom 1 (< 1%)
Islamabad, Pakistan 1 (< 1%)
Greater Faro Area, Portugal 1 (< 1%)
Lugano Metropolitan Area, Switzerland 1 (< 1%)
Baoding, China 1 (< 1%)
Bargu, Nigeria 1 (< 1%)
Greater Pittsburgh Region 1 (< 1%)
Beirut, Lebanon 1 (< 1%)
Wrexham, United Kingdom 1 (< 1%)
Horsham, United Kingdom 1 (< 1%)
Tel Aviv-Yafo, Israel 1 (< 1%)
Greater Syracuse-Auburn Area 1 (< 1%)
Greater Malmö Metropolitan Area, Sweden 1 (< 1%)
Columbus, Ohio Metropolitan Area 1 (< 1%)
Angeles, Philippines 1 (< 1%)
Others 241 (37.7%)

Part 9: Scoop.it Platform: Aviva Launched Three Journals since 2013

Introduction

Scoop.it Platform: Aviva Launched Three Journals since 2013 – a mini vault of N = 888 article titles.

The plan is that in 2026 this “Expert Culled Entries Data Set” will be used to create “hybrid curations” aka “Human Guided AI Training Model for Content Creation” thus, Part 9 represents Data repository for development of a new Method in LPBI Group’s Composition of Methods (COM).
The new method “hybrid curations” aka “Human Guided AI Training Model for Content Creation” will be developed by Aviva using Grok as 1st choice or other LLM top actors.
One may think that this “Expert Culled Entries Data Set from Scoop.it” represents a sub-IP Asset Class residing inside IP Asset Class I: The Journal. it occupies 45 pages of Posts Titles in the Journal which comprises of

(a) 318 pages of Posts Titles

6,347 items Published (6,275) First page Previous page Current Page of 318

and

(b) 24 pages of Pages Titles [All Tabs and All Nested Pages of these Tabs].

480 items [ [Published (470)]

Current Page of 24 Next page Last page

4. One may think that this “Expert Culled Entries Data Set from Scoop.it” represents a Data Type in IP Asset Class V: Media Gallery of Biological Images, namely another Type of Image. Thus, N = 888 new Images would need to be added to >7,000 items in the Media Gallery which will be classified by AI and then Classification will be validated by Human, into the following six types [Most likely, NEW types will emerged during the classification, assuming Genomics Images will require its own Sub-types classification:

Type 1: Analytics
Type 2: Word Clouds: AI in Medical Text Analysis with NLP
Type 3: Biological images
Type 4: People of Note
Type 5: Cover Pages of Books Published by LPBI Group.
Type 6: Genomics Research (mRNA) and Drug Activity

5. Here, I exercise my liberty to assert that on 1/3/2026,

the Scoop.it [N = 888] continues to reside in the Journal.
However, it requires assignment as Part 9 in LPBI Group’s Composition of Methods (COM).

It is on that date, that the development of “hybrid curations” aka “Human Guided AI Training Model for Content Creation” status is announced as PENDING and is for 2026 consideration for a collaboration with a leading LLM actor.
It is on that date the Scoop.it database repository [data set] has the following format:

Article Name & URL	Scoop.it
	Aviva’s 3
	Journals
#1	Cardiovascular and vascular imaging
Diagnosis of Double-Chambered Left Ventricle Using Advanced Cardiovascular Imaging
See on www.mdlinx.com
https://pharmaceuticalintelligence.com/2013/05/14/diagnosis-of-double-chambered-left-ventricle-using-advanced-cardiovascular-imaging/

#2	Cardiotoxicity
Obesity Surgery and High Blood Pressure – AlberniPortal.ca
See on www.alberniportal.ca
https://pharmaceuticalintelligence.com/2013/05/14/obesity-surgery-and-high-blood-pressure-alberniportal-ca/

#3	Cardiotoxicity
ICU Checklist Avoids Unplanned Readmissions – Pharmacy Practice News
See on www.pharmacypracticenews.com
https://pharmaceuticalintelligence.com/2013/05/14/icu-checklist-avoids-unplanned-readmissions-pharmacy-practice-news/

#4	Cardiotoxicity
Hypertension Drug Appears to Relieve Psychosis – PsychCentral.com
See on psychcentral.com
https://pharmaceuticalintelligence.com/2013/05/14/hypertension-drug-appears-to-relieve-psychosis-psychcentral-com/

#5	Cardiovascular Disease: PHARMACO-THERAPY
CETP, Alzheimer’s, Monty Hall, and Roulette. And Goats.. In the Pipeline:
See on pipeline.corante.com
https://pharmaceuticalintelligence.com/2013/05/16/cetp-alzheimers-monty-hall-and-roulette-and-goats-in-the-pipeline/

These are the THREE Journals launched in 0213 by Aviva Lev-Ari, PhD, RN on Scoop.it

9.1 Journal launched by Aviva Lev-Ari on Cardiovascular and vascular imaging: — 5.5K views (2017 data)

9.2 Journal launched by Aviva Lev-Ari on Cardiotoxicity – 693 views (2017 data)

9.3 Journal launched by Aviva Lev-Ari on PHARMACOTHERAPY

4.3K views (2017 data)

To access these Journal one needs to subscribe on Scoop.it website.

Program #4:

Scoop.it

In May 2013 Aviva Launched THREE Journals on the Scoop.it Platform to develop and enrich the Cardiovascular (CVD) Specialty in our Journal.

The effort of outreach for content on CVD resulted in the existence of 888 Entry titles (14% of 6,725) for content development. Aviva spent 2 hours every day for 2 years, screening hundreds of titles in the topic of each of the three Journals, below. WordPress had an agreement with Scoop.it, thus, an Entity Title selection had generated a Post on our Journal. Aviva intended to use each culled title as an entry in the Journal as a place holder on which she will develop a full blown Curation. Very few were pursued. One that was developed is “Renal Denervation”. Place that subject in the SEARCH BOX of the Journal and get all articles on this topic. Read Human created curations.

In THIS ARCHIVE we find a mini-vault, Domain-aware in Aviva’s domain knowledge expertise that was not further developed beyond been recorded as a Pipeline for 2019 Future Positioning, see article, below.

Clicks for all days ending 2018-04-02 (Summarized) – All Time

http://www.scoop.it

1,316

The effort ended when Scoop.it changed the free access of WordPress websites to a subscription-based term (2017-18). Aviva’s involvement with the BioMed e-Series took main stage following Dr. Larry’s diagnosis and medical leave on 12/2016.

The Journal VIEWS on the Scoop.it Platform were recorded on 2018-04-02 (Summarized) – All Time

1. Journal launched by Aviva Lev-Ari on Cardiovascular and vascular imaging:

Cardiovascular and vascular imaging

5.5K views

2. Journal launched by Aviva Lev-Ari on Cardiotoxicity

Cardiotoxicity

693 views

3. Journal launched by Aviva Lev-Ari on PHARMACOTHERAPY

Cardiovascular Disease: PHARMACO-THERAPY

4.3K views

To access these Journal one needs to subscribe on Scoop.it website.

LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present [2019]

https://pharmaceuticalintelligence.com/2019-vista/lpbis-pipeline-map-a-positioning-perspectives-an-outlook-to-the-future-from-the-present/

It is interesting that Scoop.it is included in the LIST of Top Referrers to our Journal

Who are the TOP Referrers for pharmaceuticalintelligence.com?

https://pharmaceuticalintelligence.com/2017/05/09/who-are-the-top-referrers-for-pharmaceuticalintelligence-com/

Below, I compiled 10% of the Scoop.it mini-vault (88 Entry articles, Pages 45 – 40 (the more recent 13 entries on Page 40 are #89 to #102, beyond 88 = 10%, not YET recorded in the Table).

Entry #89 to Entry #888 represent the 90% left UNRECORDED in the Table. The task of recording #89 to #888 is PENDING.

This Mini-Vault could function, at least in the following modalities:

(1) as a SANDBOX for AI to generate curations under Aviva’s Expert Guidance

(2) on the OUTPUT of the AI Training on “How-to-Generate-Curations-Under-Expert Guidance” to Pilot the AUTONOMOUS SYSTEMS and

(3) ADD N=888 article entries for AI generated curations with Human Guidance to the current 6,275 Journal articles as fully flag articles (With ID: as AI generated with Human guidance) for LLM with existing curations on these topics and across articles in the following categories of research:

Cardiac and Cardiovascular Surgical Procedures (326 articles)
Frontiers in Cardiology and Cardiovascular disorders (928 articles)
Cardiovascular pharmacogenomics (171 articles)
Medical Imaging (163 articles)
Pharmacotherapy of cardiovascular disease (266 articles)

(4) Interest may arise for new consideration of using Scoop.it with subscription in the future.

In the Journal, 888 Scoop.it items are recorded,

First page« Previous page‹ Current Page 45 of 45 › »

Below, I compiled 10% of the Scoop.it mini-vault (88 Entry articles, Pages 45 – 40 (the more recent 13 entries on Page 40 are #89 to #102, beyond 88 = 10%, not YET recorded in the Table to complete Page 40).

Entry #89 to Entry #888 represent the 90% left UNRECORDED in the Table. The task of recording #89 to #888 is PENDING.

Article Name & URL	Scoop.it
	Aviva’s 3
	Journals
#1	Cardiovascular and vascular imaging
Diagnosis of Double-Chambered Left Ventricle Using Advanced Cardiovascular Imaging
See on www.mdlinx.com
https://pharmaceuticalintelligence.com/2013/05/14/diagnosis-of-double-chambered-left-ventricle-using-advanced-cardiovascular-imaging/

#2	Cardiotoxicity
Obesity Surgery and High Blood Pressure – AlberniPortal.ca
See on www.alberniportal.ca
https://pharmaceuticalintelligence.com/2013/05/14/obesity-surgery-and-high-blood-pressure-alberniportal-ca/

#3	Cardiotoxicity
ICU Checklist Avoids Unplanned Readmissions – Pharmacy Practice News
See on www.pharmacypracticenews.com
https://pharmaceuticalintelligence.com/2013/05/14/icu-checklist-avoids-unplanned-readmissions-pharmacy-practice-news/

#4	Cardiotoxicity
Hypertension Drug Appears to Relieve Psychosis – PsychCentral.com
See on psychcentral.com
https://pharmaceuticalintelligence.com/2013/05/14/hypertension-drug-appears-to-relieve-psychosis-psychcentral-com/

#5	Cardiovascular Disease: PHARMACO-THERAPY
CETP, Alzheimer’s, Monty Hall, and Roulette. And Goats.. In the Pipeline:
See on pipeline.corante.com
https://pharmaceuticalintelligence.com/2013/05/16/cetp-alzheimers-monty-hall-and-roulette-and-goats-in-the-pipeline/

#6	Cardiovascular Disease: PHARMACO-THERAPY
10 sensor innovations driving the digital health revolution
See on bionic.ly
https://pharmaceuticalintelligence.com/2013/05/16/10-sensor-innovations-driving-the-digital-health-revolution/

#7	Cardiovascular Disease: PHARMACO-THERAPY
How Social Media, Mobile Are Playing a Bigger Part in Healthcare
See on mashable.com
https://pharmaceuticalintelligence.com/2013/05/16/how-social-media-mobile-are-playing-a-bigger-part-in-healthcare/

#8	Cardiovascular and vascular imaging
The e-Medicine Explosion \| MIT Technology Review
www.technologyreview.com
https://pharmaceuticalintelligence.com/2013/05/16/the-e-medicine-explosion-mit-technology-review/

#9	Cardiovascular Disease: PHARMACO-THERAPY
AT13148 – A Novel Oral Multi-AGC Kinase Inhibitor Has Potent Antitumor Activity
See on clincancerres.aacrjournals.org
https://pharmaceuticalintelligence.com/2013/05/16/at13148-a-novel-oral-multi-agc-kinase-inhibitor-has-potent-antitumor-activity/

#10	Amazing Science
New device can extract human DNA with full genetic data in minutes
See on www.washington.edu
https://pharmaceuticalintelligence.com/2013/05/16/new-device-can-extract-human-dna-with-full-genetic-data-in-minutes/

#11	Cardiovascular Disease: PHARMACO-THERAPY
Bitcoin Network Speed 8 Times Faster than Top 500 Supercomputers Combined
See on www.thegenesisblock.com
https://pharmaceuticalintelligence.com/2013/05/16/bitcoin-network-speed-8-times-faster-than-top-500-supercomputers-combined/

#12	Cardiovascular Disease: PHARMACO-THERAPY
ECOSPHERE: Social media meets 3D digital art
See on www.youtube.com
https://pharmaceuticalintelligence.com/2013/05/16/ecosphere-social-media-meets-3d-digital-art/

#13	Cardiovascular and vascular imaging
Stenosis, ischemia and heart failure
http://t.co/jokVvUsfTF)…
See on www.youtube.com
https://pharmaceuticalintelligence.com/2013/05/16/stenosis-ischemia-and-heart-failure/

#14	Cardiovascular and vascular imaging
Clot Busters May Not Be Best for Major Stroke – MedPage Today
See on www.medpagetoday.com
https://pharmaceuticalintelligence.com/2013/05/16/clot-busters-may-not-be-best-for-major-stroke-medpage-today-medpage-today/

#15	Cardiovascular and vascular imaging
Tissue Injury Has Lead in New Stroke Definition – MedPage Today – MedPage Today
See on www.medpagetoday.com
https://pharmaceuticalintelligence.com/2013/05/16/tissue-injury-has-lead-in-new-stroke-definition-medpage-today-medpage-today/

#16	Cardiovascular and vascular imaging
ANN ARBOR: New program at UM will help cancer patients deal with heart … – Heritage Newspapers
See on www.heritage.com
https://pharmaceuticalintelligence.com/2013/05/16/ann-arbor-new-program-at-um-will-help-cancer-patients-deal-with-heart-heritage-newspapers/

#17	Cardiovascular and vascular imaging
Your Health: Gut problems can have multiple causes – Richmond Times Dispatch
See on www.timesdispatch.com
https://pharmaceuticalintelligence.com/2013/05/16/your-health-gut-problems-can-have-multiple-causes-richmond-times-dispatch/

#18	Cardiovascular and vascular imaging
Detection and quantification of myocardial perfusion … – MDLinx
See on www.mdlinx.com
https://pharmaceuticalintelligence.com/2013/05/16/detection-and-quantification-of-myocardial-perfusion-mdlinx/

#19	Cardiovascular and vascular imaging
Adding dose, cost info to decision support sways exam ordering
See on www.auntminnie.com
https://pharmaceuticalintelligence.com/2013/05/16/adding-dose-cost-info-to-decision-support-sways-exam-ordering/

#20	Cardiovascular and vascular imaging
When less is more: New protocol limits use of SPECT MPI – Medical Xpress – Medical Xpress
See on medicalxpress.com
https://pharmaceuticalintelligence.com/2013/05/16/when-less-is-more-new-protocol-limits-use-of-spect-mpi-medical-xpress-medical-xpress/

#21	Cardiovascular and vascular imaging
The Most Expensive Hospital in America – Becker’s Hospital Review
See on www.beckershospitalreview.com
https://pharmaceuticalintelligence.com/2013/05/21/the-most-expensive-hospital-in-america-beckers-hospital-review/

#22	Cardiotoxicity
JNC 2013: Simplified BP Goal in Sight – MedPage Today
See on www.medpagetoday.com
https://pharmaceuticalintelligence.com/2013/05/21/jnc-2013-simplified-bp-goal-in-sight-medpage-today-medpage-today/

#23	Cardiotoxicity
Novel Approach to Resistant Hypertension Reported – Renal and Urology News
See on www.renalandurologynews.com
https://pharmaceuticalintelligence.com/2013/05/21/novel-approach-to-resistant-hypertension-reported-renal-and-urology-news/

#24	Cardiovascular Disease: PHARMACO-THERAPY
Resistant Hypertension Responds to Renal Denervation – Renal and Urology News
See on www.renalandurologynews.com
https://pharmaceuticalintelligence.com/2013/05/21/resistant-hypertension-responds-to-renal-denervation-renal-and-urology-news/

#25	Cardiovascular Disease: PHARMACO-THERAPY
Scientists unite to solve mystery of mental illness and neurological conditions – Wellcome Trust
See on www.wellcome.ac.uk
https://pharmaceuticalintelligence.com/2013/05/21/scientists-unite-to-solve-mystery-of-mental-illness-and-neurological-conditions-wellcome-trust/

#26	Cardiotoxicity
Top 10 Cardio Drugs 2012 – FiercePharma
See on www.fiercepharma.com
https://pharmaceuticalintelligence.com/2013/05/21/top-10-cardio-drugs-2012-fiercepharma/

#27	Cardiovascular and vascular imaging
Scientists prevent heart failure in mice
See on www.mpibpc.mpg.de
https://pharmaceuticalintelligence.com/2013/05/29/scientists-prevent-heart-failure-in-mice/


#28	Cardiovascular and vascular imaging
New studies outline cardiovascular risk in lupus patients
See on
www.internalmedicinenews.com
https://pharmaceuticalintelligence.com/2013/05/29/new-studies-outline-cardiovascular-risk-in-lupus-patients/

#29	Cardiovascular and vascular imaging
Myocardial Ischemia – Pipeline Review, H1 2013 – New Market Study Published – SBWire (press release)
See on www.sbwire.com
https://pharmaceuticalintelligence.com/2013/05/29/myocardial-ischemia-pipeline-review-h1-2013-new-market-study-published-sbwire-press-release/

#30	Cardiovascular Disease: PHARMACO-THERAPY
Antidepressant may reduce mental stress-induced myocardial …
See on www.2minutemedicine.com
https://pharmaceuticalintelligence.com/2013/05/29/antidepressant-may-reduce-mental-stress-induced-myocardial/

#31	Cardiovascular Disease: PHARMACO-THERAPY
New drug treatment can control damaging stress – WRAL.com
See on www.wral.com
https://pharmaceuticalintelligence.com/2013/05/29/new-drug-treatment-can-control-damaging-stress-wral-com/

#32	Cardiovascular Disease: PHARMACO-THERAPY
CoQ10 suggested to be added to standard heart failure therapy – Examiner.com
See on www.examiner.com
https://pharmaceuticalintelligence.com/2013/05/29/coq10-suggested-to-be-added-to-standard-heart-failure-therapy-examiner-com/

#33	Cardiovascular Disease: PHARMACO-THERAPY
Heart Failure Treatment Improves, But Death Rate Remains High : NPR
See on www.npr.org
https://pharmaceuticalintelligence.com/2013/05/29/heart-failure-treatment-improves-but-death-rate-remains-high-npr/

#34	Cardiovascular Disease: PHARMACO-THERAPY
Angry outbursts are linked to increased risk of heart attack – Washington Post
See on www.washingtonpost.com
https://pharmaceuticalintelligence.com/2013/05/29/angry-outbursts-are-linked-to-increased-risk-of-heart-attack-washington-post/

#35	Cardiotoxicity
G Cover When the brain is under attack – Boston Globe
See on www.bostonglobe.com
https://pharmaceuticalintelligence.com/2013/05/29/g-cover-when-the-brain-is-under-attack-boston-globe/


#36	Cardiotoxicity
BP reductions with EnligHTN ablation system sustained at 1 year – Healio
See on www.healio.com
https://pharmaceuticalintelligence.com/2013/05/29/bp-reductions-with-enlightn-ablation-system-sustained-at-1-year-healio/

#36	Cardiovascular Disease: PHARMACO-THERAPY
First drug to improve heart failure mortality in over a decade – HealthCanal.com
See on www.healthcanal.com
https://pharmaceuticalintelligence.com/2013/06/03/first-drug-to-improve-heart-failure-mortality-in-over-a-decade-healthcanal-com/

#37	Cardiovascular Disease: PHARMACO-THERAPY
Meta-analysis: Heart Failure Worsens Short-term Prognosis of NSTE-ACS Patients – TCTMD
See on www.tctmd.com
https://pharmaceuticalintelligence.com/2013/06/06/meta-analysis-heart-failure-worsens-short-term-prognosis-of-nste-acs-patients-tctmd/

#38	Amazing Science
Combined anti-CTLA4 and anti-PD1 immunotherapy shows promising results against advanced melanoma
See on news.yale.edu
https://pharmaceuticalintelligence.com/2013/06/07/combined-anti-ctla4-and-anti-pd1-immunotherapy-shows-promising-results-against-advanced-melanoma/

#39	Amazing Science
Yale scientists develop video-rate nanoscopy to peer deep into a cell in real time
See on news.yale.edu
https://pharmaceuticalintelligence.com/2013/06/07/yale-scientists-develop-video-rate-nanoscopy-to-peer-deep-into-a-cell-in-real-time/

#40	Cardiovascular Disease: PHARMACO-THERAPY
ASE defines practice standards for cardiac US
See on www.auntminnie.com
https://pharmaceuticalintelligence.com/2013/06/07/ase-defines-practice-standards-for-cardiac-us/

#41	Cardiovascular Disease: PHARMACO-THERAPY
Lexapro may improve heart health – eMaxHealth
See on news.google.com
https://pharmaceuticalintelligence.com/2013/06/07/lexapro-may-improve-heart-health-emaxhealth/


#42	Cardiovascular Disease: PHARMACO-THERAPY
Cocaine-induced coronary-artery vasoconstriction. [N Engl J Med. 1989] – PubMed – NCBI
See on www.ncbi.nlm.nih.gov
https://pharmaceuticalintelligence.com/2013/06/07/cocaine-induced-coronary-artery-vasoconstriction-n-engl-j-med-1989-pubmed-ncbi/

#43	Cardiovascular Disease: PHARMACO-THERAPY
Heart-failure admissions and mortality highest in winter and on weekends – TheHeart.Org
See on www.theheart.org
https://pharmaceuticalintelligence.com/2013/06/07/heart-failure-admissions-and-mortality-highest-in-winter-and-on-weekends-theheart-org/

#44	Cardiovascular Disease: PHARMACO-THERAPY
Emergency Medicine PharmD: Calcium Channel Blockers and Beta …
See on empharmd.blogspot.com
https://pharmaceuticalintelligence.com/2013/06/13/emergency-medicine-pharmd-calcium-channel-blockers-and-beta/

#45	Cardiovascular Disease: PHARMACO-THERAPY
News digest – inherited cancer genes, beta-blockers, non-Hodgkin …
See on scienceblog.cancerresearchuk.org
https://pharmaceuticalintelligence.com/2013/06/13/news-digest-inherited-cancer-genes-beta-blockers-non-hodgkin/

#46	Cardiovascular and vascular imaging
The Future of Getting Paid to Be Healthy
See on www.theatlantic.com
https://pharmaceuticalintelligence.com/2013/06/18/the-future-of-getting-paid-to-be-healthy/

#47	Cardiovascular and vascular imaging
Tips for new TAVR centers
See on www.theheart.org
https://pharmaceuticalintelligence.com/2013/06/18/tips-for-new-tavr-centers/

#48	Cardiovascular and vascular imaging
The best city to have a heart attack?
See on www.foxnews.com
https://pharmaceuticalintelligence.com/2013/06/18/the-best-city-to-have-a-heart-attack/

#49	Cardiovascular and vascular imaging
The Bank Where Doctors Can Stash Your Genome
See on mashable.com
https://pharmaceuticalintelligence.com/2013/06/21/the-bank-where-doctors-can-stash-your-genome/

#50	Cardiovascular and vascular imaging
Cholesterol Removed From Blood With New Method
See on www.redorbit.com
https://pharmaceuticalintelligence.com/2013/06/21/cholesterol-removed-from-blood-with-new-method/

#51	Cardiovascular and vascular imaging
Surgeons complete clinical trial on novel two-part heart valve
See on www.cxvascular.com
https://pharmaceuticalintelligence.com/2013/06/21/surgeons-complete-clinical-trial-on-novel-two-part-heart-valve/

#52	Cardiovascular and vascular imaging
Extra Weight Won’t Worsen Aortic Stenosis
See on www.medpagetoday.com
https://pharmaceuticalintelligence.com/2013/06/21/extra-weight-wont-worsen-aortic-stenosis/

#53	Cardiovascular and vascular imaging
Transulnar approach should not be used as default strategy for coronary procedures
See on www.cxvascular.com
https://pharmaceuticalintelligence.com/2013/06/21/transulnar-approach-should-not-be-used-as-default-strategy-for-coronary-procedures/

#54	Cardiovascular and vascular imaging
Extreme obesity linked to in-hospital mortality in PCI-treated patients
See on news.google.com
https://pharmaceuticalintelligence.com/2013/06/21/extreme-obesity-linked-to-in-hospital-mortality-in-pci-treated-patients/

#55	Cardiovascular and vascular imaging
Comparative study on myocardial protection by high dose GIK and …
See on www.stmpapers.com
https://pharmaceuticalintelligence.com/2013/06/21/comparative-study-on-myocardial-protection-by-high-dose-gik-and/

#56	Cardiovascular and vascular imaging
Our Voice: We need to understand why health care costs vary so much – The Desert Sun
See on news.google.com
https://pharmaceuticalintelligence.com/2013/06/21/our-voice-we-need-to-understand-why-health-care-costs-vary-so-much-the-desert-sun/

#57	Cardiovascular and vascular imaging
Plavix warning may not be necessary – CNN (blog)
See on thechart.blogs.cnn.com
https://pharmaceuticalintelligence.com/2013/06/26/plavix-warning-may-not-be-necessary-cnn-blog/

#58	Cardiovascular and vascular imaging
Sudden cardiac deaths like one that fell ‘Sopranos’ star Gandolfini can be … – Bradenton Herald
See on www.bradenton.com
https://pharmaceuticalintelligence.com/2013/06/26/sudden-cardiac-deaths-like-one-that-fell-sopranos-star-gandolfini-can-be-bradenton-herald/

#59	Cardiovascular and vascular imaging
Cardiogenic Shock \| Diseases And Disorders
See on www.diseasesanddisorders.org
https://pharmaceuticalintelligence.com/2013/06/26/cardiogenic-shock-diseases-and-disorders/


#60	Cardiovascular and vascular imaging
ALIAS: No Benefit of Albumin in Acute Stroke – Medscape
See on login.medscape.com

https://pharmaceuticalintelligence.com/2013/06/26/alias-no-benefit-of-albumin-in-acute-stroke-medscape/


#61	Cardiovascular and vascular imaging
Gastric Tissue Damage Analysis Generated by Ischemia – Hindawi …
See on www.hindawi.com
https://pharmaceuticalintelligence.com/2013/06/26/gastric-tissue-damage-analysis-generated-by-ischemia-hindawi/

#62	Cardiovascular and vascular imaging
ISCHEMIA without PAIN \| MDadvice
See on www.mdadvice.com
https://pharmaceuticalintelligence.com/2013/06/26/ischemia-without-pain-mdadvice/

#63	Cardiovascular and vascular imaging
Critical Care \| Abstract \| Cardiac ischemia in patients with septic …
See on ccforum.com
https://pharmaceuticalintelligence.com/2013/06/26/critical-care-abstract-cardiac-ischemia-in-patients-with-septic/

#64	Cardiovascular and vascular imaging
Tissue obtained during heart surgery elucidates autophagy changes during … – 2 Minute Medicine
See on www.2minutemedicine.com
https://pharmaceuticalintelligence.com/2013/06/26/tissue-obtained-during-heart-surgery-elucidates-autophagy-changes-during-2-minute-medicine/

#65	Cardiovascular and vascular imaging
Intermedin protects against myocardial ischemia-reperfusion injury …
See on www.cardiab.com
https://pharmaceuticalintelligence.com/2013/06/26/intermedin-protects-against-myocardial-ischemia-reperfusion-injury/


#66	Cardiovascular and vascular imaging
Remote Preconditioning Prior to PCI Demonstrates Long-term Ischemic Benefits – TCTMD
See on news.google.com
https://pharmaceuticalintelligence.com/2013/06/26/remote-preconditioning-prior-to-pci-demonstrates-long-term-ischemic-benefits-tctmd
/
#67	Cardiovascular and vascular imaging
Stress CMR for CAD Matches Prognostic Utility of More Established Techniques – TCTMD
See on news.google.com
https://pharmaceuticalintelligence.com/2013/06/26/stress-cmr-for-cad-matches-prognostic-utility-of-more-established-techniques-tctmd/


#68	Cardiovascular Disease: PHARMACO-THERAPY
DA Adds Cardiac Drugs to Watch List – TOPROL-XL®
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019962s038lbl.pdf
FDA Safety Changes: Toprol XL, Revlimid, Fludara
https://pharmaceuticalintelligence.com/2013/06/26/fda-adds-antinausea-cardiac-drugs-to-watch-list-medscape/

#69	Cardiovascular Disease: PHARMACO-THERAPY
Pacemakers , rather than beta blockers , could be a better treatment for heart … – Toronto NewsFIX
See on www.newsfix.ca
https://pharmaceuticalintelligence.com/2013/06/26/pacemakers-rather-than-beta-blockers-could-be-a-better-treatment-for-heart-toronto-newsfix/

#70	Cardiotoxicity
Weight loss does not reduce heart, stroke woes in overweight Type 2 diabetics – UAB News
See on www.uab.edu
https://pharmaceuticalintelligence.com/2013/06/26/weight-loss-does-not-reduce-heart-stroke-woes-in-overweight-type-2-diabetics-uab-news/

#71	Cardiotoxicity
Better use of medicines could save billions – Harvard Health Publications (blog)
See on www.health.harvard.edu
https://pharmaceuticalintelligence.com/2013/06/26/better-use-of-medicines-could-save-billions-harvard-health-publications-blog/

Waste and Harm in the Treatment of Mild Hypertension – MedPage Today	Cardiotoxicity
See on www.medpagetoday.com
https://pharmaceuticalintelligence.com/2013/06/26/waste-and-harm-in-the-treatment-of-mild-hypertension-medpage-today/

#72	Cardiovascular and vascular imaging
Ischemic Preconditioning Reduces Myocardial Necrosis in Elective PCI – TCTMD
See on www.tctmd.com
https://pharmaceuticalintelligence.com/2013/07/10/ischemic-preconditioning-reduces-myocardial-necrosis-in-elective-pci-tctmd/


#73	Cardiovascular and vascular imaging
Traditional Chinese Medicine Nonsignificant Effect in Stroke – Medscape
See on login.medscape.com
https://pharmaceuticalintelligence.com/2013/07/10/traditional-chinese-medicine-nonsignificant-effect-in-stroke-medscape/


#74	Cardiovascular and vascular imaging
Perfusion Art: “Shrink Wrap” \| Circuit Surfers
See on circuitsurfers.com
https://pharmaceuticalintelligence.com/2013/07/10/perfusion-art-shrink-wrap-circuit-surfers/

#75	Cardiovascular and vascular imaging
Drug-Eluting Balloons Lower TLR in Diabetics with Critical Limb Ischemia – TCTMD
See on www.tctmd.com
https://pharmaceuticalintelligence.com/2013/07/10/drug-eluting-balloons-lower-tlr-in-diabetics-with-critical-limb-ischemia-tctmd/

#76	Cardiovascular Disease: PHARMACO-THERAPY
A newer beta blocker may be less of a psychiatric scourge
See on www.foxnews.com
https://pharmaceuticalintelligence.com/2013/07/10/a-newer-beta-blocker-may-be-less-of-a-psychiatric-scourge/

#77	Cardiovascular Disease: PHARMACO-THERAPY
Comparing high blood pressure medication in heart patients – Toronto NewsFIX
See on www.newsfix.ca
https://pharmaceuticalintelligence.com/2013/07/10/comparing-high-blood-pressure-medication-in-heart-patients-toronto-newsfix/

#78	Cardiovascular Disease: PHARMACO-THERAPY
Comparison of blood pressure drugs rules against beta blockers – The Almagest
See on www.thealmagest.com
https://pharmaceuticalintelligence.com/2013/07/10/comparison-of-blood-pressure-drugs-rules-against-beta-blockers-the-almagest/
#79	Cardiovascular Disease: PHARMACO-THERAPY
Beta blockers help women with heart failure – The Almagest
See on www.thealmagest.com
https://pharmaceuticalintelligence.com/2013/07/10/beta-blockers-help-women-with-heart-failure-the-almagest/
#80	Cardiovascular Disease: PHARMACO-THERAPY
Gender Differences and Acute Coronary Syndrome: The Clinical Implications – Pharmacy Times
See on www.pharmacytimes.com
https://pharmaceuticalintelligence.com/2013/07/10/gender-differences-and-acute-coronary-syndrome-the-clinical-implications-pharmacy-times/

#81	Cardiovascular and vascular imaging
Lost in Translation – Scientist
See on www.the-scientist.com
https://pharmaceuticalintelligence.com/2013/07/18/lost-in-translation-scientist/

#82	Cardiovascular and vascular imaging
UTHealth CLOTBUST-ER Studies Ultrasound in Combination With tPA As … – BioNews Texas
See on bionews-tx.com
https://pharmaceuticalintelligence.com/2013/07/18/uthealth-clotbust-er-studies-ultrasound-in-combination-with-tpa-as-bionews-texas/

#83	Cardiovascular Disease: PHARMACO-THERAPY
CardiologyQuiz – Daily questions on cardiology! \| Wisr
See on wisr.com
https://pharmaceuticalintelligence.com/2013/07/18/cardiologyquiz-daily-questions-on-cardiology-wisr/


#84	Cardiotoxicity
Greatly increased risk of stroke for patients who don’t adhere to antihypertensive drug treatments …
See on www.sciencecodex.com
https://pharmaceuticalintelligence.com/2013/07/18/greatly-increased-risk-of-stroke-for-patients-who-dont-adhere-to-anti/

#85	Cardiovascular and vascular imaging
Critical Care Bulletin: Cardiac ischemia in patients with septic shock …
See on critcare08.blogspot.com
https://pharmaceuticalintelligence.com/2013/07/23/critical-care-bulletin-cardiac-ischemia-in-patients-with-septic-shock/



#86	Cardiovascular and vascular imaging
Stress CT perfusion matches SPECT for detecting myocardial ischemia
See on cardiology.hcsm.in
https://pharmaceuticalintelligence.com/2013/07/23/stress-ct-perfusion-matches-spect-for-detecting-myocardial-ischemia/

#87	Cardiovascular and vascular imaging
Lipoxin A4 Preconditioning and Postconditioning Protect Myocardial …
See on www.hindawi.com
https://pharmaceuticalintelligence.com/2013/07/28/lipoxin-a4-preconditioning-and-postconditioning-protect-myocardial/

#88	Cardiovascular and vascular imaging
Drug Combo Boosts Neurologically Intact Survival After CPR – Medscape
See on login.medscape.com


10% of Scoop.it are recorded ABOVE from the 1^st to the most recent – to continue from #89 to #888 Go to Dashboard à> All Postsà> Search Box type Scoop.it à> go to page 45, last Page, now click back to 44,43,43,41,40
On each Page you scroll to the bottom and walk up on the time line toward the MOST recent Entries, #888 is the most recent, #1 was the 1^st entry from Scoop.it on our Journal.
#89 On Page 40,
13 entries are left to move to Page 39.

Part 10: Multimodal Methods of Execution Infrastructure (EI) for AI Data Analyses and Exposition of the Analyses Results

Part 10 presents the 1st Corporate Application of the Novel Method.
Part 10 presents the Published Source(s) of the 1st Corporate Application of the Novel Method.

10.1 Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation.

1st Corporate Application of the Novel Method.

Pending Schedule: Zoom Multi Media meeting between Top Leader in AI software Development and LPBI Group exploring future Collaboration.

Published Source(s) of the 1st Corporate Application of the Novel Method.

Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods

Authors:

Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief, Journal and BioMed e-Series, LPBI Group)
Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2026/01/06/workflow-for-dynamic-linkage-and-transition-between-two-authoring-systems-lpbi-groups-wordpress-com-multi-authors-authoring-system-and-microsoft-powerpoint-product-for-slide-show-presentation-par/

10.2 Method for Data Set Selection for Grok’s LLM & Causal Reasoning – Multimodal Data Set: Text & Images

1st Corporate Application of the Novel Method.

Pilot Study Grok 4.1 and LPBI Group’s Contents

21 articles shared with UK-based TOP NLP company, 2021 – benchmarking study
20 articles selected from 3 categories of research in Cancer – Discovery study
List of Articles in Book Chapters for DYAD & TRIAD Analysis, NLP and Causal Reasoning
Chapters in e-Books:

Series A, Cardiovascular, Translational Medicine, Volume 4, Part One, Chapter 2

Series A, Cardiovascular, Regenerative Medicine, Volume 4, Part Two, Chapter 1

Series B, Genomics, Volume 1, Chapter 3

Series D, Immunology, Volume 3, Chapter 2

Methodologies Used for Each Row

(Full reproducibility — all tools, versions, and parameters)

Row	Method	Tools & Parameters	Notes
1	UK-based TOP NLP company, 2021 static NLP	Proprietary keyword + co-occurrence rules (text only)	Exact replica of 2021 run (673 relations)
2	Grok static NLP	Regex + co-occurrence on text only	No images, no ontology
3	Grok 4.1 full multimodal	Aurora vision + LPBI ontology tree + RLHF reasoning	Text + 25 images + CSO criteria (subsets, agonist/antagonist)
4	Grok on CSO’s 20 articles from 3 categories	Same as Row 3	Category-specific weighting
5	Grok on Aviva CVD Chapter 1	Same as Row 3	Mitochondria stress focus
6	Grok on Aviva CVD Chapter 2	Same as Row 3	Stem cell regeneration focus
7	Grok on CSO Oncology Chapter 1	Same as Row 3	Cancer genomics focus
8	Grok on CSO Immunology Chapter 2	Same as Row 3	Immune development focus
9	Combined Aviva CVD Volume 4	Same as Row 3	Merged Parts 1 & 2 for regenerative cardiology

Published Source(s) of the 1st Corporate Application of the Novel Method.

2025 Grok 4.1 Causal Reasoning & Multimodal on Identical Proprietary Oncology Corpus: From 673 to 5,312 Novel Biomedical Relationships: A Direct Head-to-Head Comparison with 2021 Static NLP – NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus Transforms Grok into the “Health Go-to Oracle”

Authors:

Stephen J. Williams, PhD (Chief Scientific Officer, LPBI Group)
Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief Journal and BioMed e-Series, LPBI Group)
Grok 4.1 by xAI

10.3 Method for Data Set Selection for Grok’s LLM & Causal Reasoning – Multimodal Data Set: Audio, Text & Images

10.3.1 Data Set Selection: Audio, Text & Images

10.3.1.1 Benchmarking Grok 4.1 vs Wolfram’s NLP & DL on the same Training Data: LPBI Group crown jewel of 13 Co-curation articles on Calcium’s role in cardiac function. [Text & Images of all types of the Media Gallery.

10.3.1.2 New data Set never analyzed by AI: A set of 36 Audio Podcasts [Audio and Script] on CVD

10.3.1.3 Other articles in IP Asset Class I: The Journal on Calcium [Text and Images]

10.3.1.4 Articles from Categories of Research on Calcium and on Atrial Fibrillation (AFib) [Text & Images]

10.3.1.5 Scoop.it Mini Vault retrievals [Text & Images]

10.3.2 Grok’s AI Modeling and Analyses Results

1st Corporate Application of the Novel Method.

Forthcoming,

2nd Joint Article by Aviva Lev-Ari, PhD, RN & Grok 4.1 by xAI

Published Source(s) of the 1st Corporate Application of the Novel Method.

2026 Grok Multimodal Causal Reasoning on Proprietary Cardiovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage

Authors:

Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief, Journal and BioMed e-Series, LPBI Group)
Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2026/01/06/2026-grok-multimodal-causal-reasoning-on-proprietary-cardiovascular-corpus-from-2021-wolfram-nlp-baseline-to-thousands-of-novel-relationships-a-second-head-to-head-validation-of-lpbi/

Part 11 – Validation Models for Execution Infrastructures

11.1 Validation Models for Data Set Selection Methods

11.2 Validation Model for Data Access Sequences prioritized by Executives for knowledge acquisition in Virtual Data Exposition about Acquisition Decision Making

11.1 Validation Models for Data Set Selection Methods

11.1.1 First Joint Article Grok 4.1 and LPBI Group Proprietary Oncology Content – Validation Model for Text and Images published 12/15/2025 by Expert A, Expert B and Grok 4.1 by xAI

Module 1: Benchmarking NLP on Expert A: Expert Selected Data Set of 25 Oncology articles and 20 Images – Uplift for Module 1 by Grok’s 2025 NLP

Module 2: LLM and Causal Reasoning on Data Set in Module 1

Uplift by Grok’s New Dyads Discovery (NDD), and
Grok’s Launch of Triad Discovery Method (TDM)

>>> Major % Uplift by

2.1 Triad Method

2.2 Therapeutic MOA properties

2.3 Image analysis of histology & pathology

Module 3: Expert A: Expert Selection of 20 articles in Dominant Oncology Categories of Research (DCR)

20 articles across 3 categories in Oncology

Articles included in Module 1 (on Text and Images)
Articles not included in Module 1 (on Text)

>>> Major Triads discovery by Grok’s LLM and Casual Reasoning (on Text)

Module 4: Expert Selections of Chapters in e-Books (ESCB)

4.1 Expert A: Genomics, Series B, Volume 1, Chapter with 8 articles

4.2 Expert A: Immunology, Series D, Volume 3, Chapter with 8 articles

4.3 Expert B: Cardiovascular, Series A, Volume 4,

Translational Chapter – 11 articles
Regenerative Chapter – 11 articles

>>> Major Triads Discovery by Grok’s LLM and Causal Reasoning (on Text)

11.1.2 Second Joint Article Grok 4.1 and LPBI Group’s Expert B, forthcoming 2/15/2026 Proprietary Cardiovascular Content, Validation model for Audio, Text Images

Module 5: Expert B Selected a 13-article Series on Calcium role in Cardiac Functions

Module 6: Benchmark NLP + DL Wolfram vs Grok 4.1 on data of Module 5

Module 7: LLM and Causal Reasoning on Data of Module 5

Module 8: Expert B selects all or subset of Articles on Calcium in the Journal for Grok’s NLP, LLM and Causal Reasoning

Module 9: Expert B selects Chapter 18 on CVD Podcasts in IP Asset Class X: Library of Podcasts for Audio, Text, Images

Module 10: Grok 4.1 uses Data in Module 9 for Training a Multimodal Model using Audio, Text, Images

Module 11: Scoop.it mini vault: Expert B selected the earliest 88 articles placed in Three Journals on Scoop.it

Module 12: Grok 4.1 to develop 1.0 version of Hybrid Co-curation by Expert B and Expert B guiding Grok using Module 11 data for Training on Co-curation

11.2 Validation Model for Data Access Sequences prioritized by Executives for knowledge acquisition in Virtual Data Exposition about Acquisition Decision Making

11.2.1 Virtual Data Exposition of Endgame: Achievement of Gold & Silver Medals in “AI in Health”

Slide show of trophies:

>>> Modules 2,3,4

>>> Modules 6,7,8,9,12

Slide show of PORTFOLIO OF IP

• IP Asset Class I: Journal: PharmaceuticalIntelligence.com

6,250 scientific articles (70% curations, creative expert opinions. 30% scientific reports).

2.4MM Views, equivalent of $50MM if downloading an article is paid market rate of $30.

• IP Asset Class II: 48 e-Books: English Edition & Spanish Edition.

155,000 pages downloaded under pay-per-view. The largest number of downloads for one e-Publisher (LPBI)

https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss

• IP Asset Class III: 100 e-Proceedings and 50 Tweet Collections of Top Biotech and Medical Global Conferences, 2013-2025

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

• IP Asset Class V: 7,500 Biological Images in our Digital Art Media Gallery, as prior art

• IP Asset Class X: +300 Audio Podcasts: Interviews with Scientific Leaders

https://pharmaceuticalintelligence.com/biomed-audio-podcast-library-lpbi-group/

In addition, other five IP assets include the following:

• IP Asset Class VIII: 18,000 Subscribers to the Journal of 6,250 articles. Journal Ontology is extremely valuable as OM (Ontology Method) for LLM, ML, NLP

• IP Asset Class IV: Composition of Methods: SOP on How create a Curation, How to Create an electronic Table of Content (eTOC), work flows for e-Proceedings and many more, Part 1 to Part 11

https://pharmaceuticalintelligence.com/sop-web-stat/

https://pharmaceuticalintelligence.com/composition-of-methods-com/

• IP Asset Class VII: Royalties paid for pages downloaded from e-Books

• IP Asset Class VI: Bios of Experts as Content Creators

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

• IP Asset Class IX: INTANGIBLES: e-Reputation: +1,200 Endorsements, Testimonials, Notable followers on X.com: Editor-in-Chief Journal American Medical Association (JAMA), Broad Institute @MIT, Big Pharma, 500 CEOs of them 300 in Biotech are 1st connection on LinkedIn, and more indicators

https://pharmaceuticalintelligence.com/intangibles-cim/

Module 13: List of Slides Titles on PPT file

Slide 1 to Slide 24

On each Slide Title Slide there is a LIVE URL to Slide’s Body on WordPress

Module 14: List of Appendices Titles on PPT file

Appendix 1 to Appendix 24

On each Appendix Title Slide their is a LIVE URL to Appendix’s Body on WordPress

Module 15:

Body of each Slide Title Slide is on a Nested WordPress Page accessed by a LIVE URL on each Slide requires Password to be shared at the beginning of the Zoom

Module 16:

Body of each Appendix is on Nested, Nested WordPress Page accessed by a LIVE URL ( different than in Module 15) on each of the Appendix Title Slide requires Password SAME as in Module 15

Validation Model is designed to learn from the 1st Zoom session the following points:

what are the knowledge priorities of the Executives:

Priority A: Endgame

Priority B: Slides Titles – All Topics covered

Priority C: Appendices Title – All Options for Deep Dive Data

Priority D: BODY of each Slide

Priority E: BODY of each Appendix

to use lessons learned for application in forthcoming Zoom sessions with same Executives

Module 17: Validation Methods:

17.1 Text Analysis of the Script of the RECORDED Zoom session

17.2 cluster of questions asked

17.3 sequence of questions

Module 18: Comparison of Priorities in Assumptions: Module 16: A,B,C,D,E vs the results obtained in Module 17: 17.1, 17.2, 17.3

Module 19: Results of Module 17 applied for architecture design of Virtual Content Exposition for 2nd Zoom

19.1

Module 18 captured that Each Executive had a different Priority list

THEN

Each Executive will receive a Personal Slide Deck

Module 18 reveals Clusters of executives for clusters of Close priorities

THEN

the 2nd session will aggregate topics in different combination than the one followed by next.

Scenario Guidance #1:

IF the interest focus is on

Universes of Intelligence as mirrored in Journal’s Ontology

IP Assets by Class

Application potential of Universes of Intelligence

Leverage of vertical integration

THEN we would prepare custom-tailored responses

Scenario Guidance #2:

The interest is to start with

What it takes to achieve Transfer of Ownership?

THEN

The discussion will focus of the details of

Slides 21, 22, 23 – only

Part 12 – Monetization Schedules for the Hybrid Model, Human & AI: System 1, System 2, System 3, System 4

SYSTEM #1: Dynamic Intelligence Tokens Exchange [Stock in trade on the Exchange: Journal articles in 4 Domain Knowledge in Healthcare]

SYSTEM #2: Dynamic Image Exchange [Stock in trade on the Exchange: Images (Prior Art)]

SYSTEM #3: Dynamic Podcast Exchange [Stock in trade on the Exchange: Podcasts on Life Sciences Discoveries in the 21st Century]

SYSTEM #4: Dynamic Conference Content Exchange [Stock in trade on the Exchange: e-Proceedings & Tweet Collections Exchange or Dated Speakers & KOLs Quote

Overview

Four Systems: Tokenized exchanges for Journal articles (4 domains), Images (prior art/NFTs), Podcasts (300+ with eTOCs growth to 3,000), Conference content (150+ e-Proceedings/Tweets).
Hybrid Model Throughout: Aviva guides Grok for classification/sorting (e.g., 757 categories → 4 domains; image types; podcast augmentation from YouTube).
Monetization Vision: B2B marketplaces on blockchain-inspired architecture (links to vision/blockchain/NFT pages), trading/licensing with ontology owners, content augmentation for #1 positioning.
Historical Ties: Charts from 2021 (BurstIQ transactions network, GTO promotion), Phase 6 review.
Growth Goals: e.g., Podcasts from +300 → 3,000 via subject-matching YouTube URLs; becoming #1 library for Grok training and user traffic.

In Grok words:

This Part 12 is a masterful capstone for COM—turning the executable infrastructure into self-sustaining, network-effect revenue engines. It directly amplifies the Gold Medal probability by showing not just one-time value but ongoing Healthcare Intelligence Hub (HIH) monetization.

SOURCE

https://grok.com/c/554d4ef5-43f6-48a5-bae2-4e133acbd526?rid=91966d17-b51d-4857-bea1-b0d17172d1eb

Chart #1: Transactions Network for the Intelligence tokens

LPBI workflow overview

Image Source:

Review Phase 6 in

https://pharmaceuticalintelligence.com/vision/

Chart #2: Content Promotion Proposal by GTO

Image Source:

Produced by GTO for collaboration between LPBI Group, BurstIQ and GTO

SYSTEM #1: Dynamic Intelligence Tokens Exchange [Stock in trade on the Exchange: Journal articles in 4 Domain Knowledge in Healthcare]

AI in Health – Intelligent Information System for Advanced Queries in the four Domain Knowledge (DK) of Healthcare:

Pharmaceutical/BioPharma,
Medical/Diagnosis and Therapeutics,
Life Sciences/Genomics and
BioMed/Biotech/Medtech

AI AGENTS activate Classification of 757 categories of research into above four Domain Knowledge achieved by a Hybrid Model:

>>> Aviva guides Grok

Best Ways to Export All 757 Categories (Name + Post Count + Description/Slug)

Here are the most practical options (from easiest to more advanced):

Recommended: Install a Free Plugin (Fastest & Cleanest)

Use WP All Export (free version sufficient for categories) or Admin Columns Pro (has export for Taxonomy tables).

Steps for WP All Export (most popular & reliable):

Install & activate “WP All Export” from WordPress.org plugins.

Go to All Export › New Export.

Select Taxonomies as the export type.

Choose Categories (or your custom taxonomy if applicable).

Drag & drop fields: Name, Slug, Description, Count (post count is included automatically), Parent, etc.

Export as CSV (opens perfectly in Excel/Google Sheets).

Run export → downloads all 757 in one file, no pagination needed.

Alternative free plugin: “WP Export Categories & Taxonomies” (simple XML export, then convert to CSV if needed).

Manual Screen Export (No Plugin Needed)

On the categories admin page (Posts > Categories or the taxonomy=category link you shared), enable Screen Options (top right) → increase “Number of items per page” to 999 (max).

This shows all 757 on one page (avoids 38 pages).

Use browser select: Click-drag to select the entire table → copy → paste into Excel/Google Sheets (columns like Name, Description, Slug, Count will separate automatically).

Quick for one-time use.

Bulk Actions on List Table

Same page: Check the checkbox to select all (or Shift-click), but “Bulk Actions” only has Edit/Delete—no Export. So not helpful here.

Advanced (If You Have Hosting Access)

Use phpMyAdmin (via your host): Export the tables wp_terms, wp_term_taxonomy, wp_term_relationships → join them for a full list with counts. But this requires SQL knowledge.

Once you have the CSV with Category Name + Count, we can easily sort/map them into your four domains (Pharma/BioPharma, Medical/Diagnosis & Therapeutics, Life Sciences/Genomics, BioMed/Biotech/Medtech) → sum articles per domain → create that exact slide you described (e.g., “Grok will train on ~X,XXX articles in Pharmaceutical/BioPharma…”).

>>>> Monetization of multilingual Intelligence Tokens on Blockchain Transactions system architecture for Journal Ontology Entities

IP Asset Class I: The Journal – 757 Categories of Research

Hybrid made Intelligence Tokens:

A. Train LLM on Four Universes each consists of multiple categories of research AI and Human validated SORTING into

1. Pharmaceutical/BioPharma,
2. Medical/Diagnosis and Therapeutics,
3. Life Sciences/Genomics and
4. BioMed/Biotech/Medtech

Grok’s Training on Four Domains of Domain-Aware “AI in Health”

Slide Title (Bold, Large, Centered): Grok’s Domain-Aware Training Corpus Four Pillars of Health AI Leadership from LPBI’s 6,275 Expert-Curated Articles

Subtitle: Mapped from Journal Ontology (~740 Categories of Research)

Main Visual/Chart Suggestion: A pie chart or bar chart showing the four domains with article counts (e.g., four segments/bars in health-themed colors: blue for Pharma, green for Medical, purple for Genomics, orange for BioMed). Add Grok/xAI icon in center.

Body Bullets (Hierarchical, Punchy):

Grok will train on four specialized fields of domain-aware AI in Health, derived from LPBI’s proprietary journal ontology:
1. Pharmaceutical/BioPharma – ~2,200 articles (oncology, pharmacotherapy, drug discovery, pipelines) – Focus: Drug repurposing, target ID, adverse events, regulatory intelligence
2. Medical/Diagnosis and Therapeutics – ~1,800 articles (cardiovascular, immunology, precision medicine, diagnostics) – Focus: Differential diagnosis, personalized plans, imaging/pathology interpretation
3. Life Sciences/Genomics – ~1,300 articles (mRNA, pharmacogenomics, gene therapy, NGS) – Focus: Variant prioritization, gene–drug–disease triads, synthetic biology
4. BioMed/Biotech/Medtech – ~975 articles (emerging tech, conferences, trends: CAR-T, AAV, wearables, devices) – Focus: Innovation scouting, due diligence, trend forecasting
Total: 6,275 human expert-curated articles (~740 ontology categories mapped and aggregated) – Each domain >975 articles → Deep, traceable domain knowledge unmatched at scale
Grok’s Edge (Callout Box): These four corpuses enable Grok’s competencies in AI-driven causal reasoning—as demonstrated in our 1st joint article—to marvel in discovery of novel biomedical relationships for mankind worldwide.
Broader Impact (Inspiring Closing Quote, Bold): “With better health and AI-created abundance on Earth, we can divert resources to space exploration and multi-planetary orbits.”

Footer: Curator: Aviva Lev-Ari, PhD, RN | January 7, 2026 | Live Demo: Oncology Pilot (7.9× uplift) – Link: https://www.linkedin.com/pulse/new-foundation-multimodal-model-healthcare-lpbi-2025-aviva-40h1e

Notes on Article Distribution among 4 DK:

The counts above are reasoned estimates based on known LPBI emphases (heavy in oncology/pharma, cardiovascular/medical, genomics tracks, and conference/biotech coverage), summing to ~6,275. For precise mapping:

The journal ontology (757 categories) would need to be exported/sorted (e.g., via WP admin or site sitemap).

B. Trade or License with Ontology owners actors AFTER ingestion for LLM

BLOCKCHAIN system design URL

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

LPBI Vision on BLOCKCHAIN Integration Strategy URL

https://pharmaceuticalintelligence.com/vision/

SYSTEM #2: Dynamic Image Exchange [Stock in trade on the Exchange: Images (Prior Art)]

AI AGENTS activate Classification of >7,000 Biological Images in six Types achieved by the Hybrid Model:

>>>> Aviva guides Grok

IP Asset Class V: Biological Images – Image Type Examples

The entire Media Gallery needs to be classified into types. Below, we feature 6 types by examples:

Type 1: Analytics
Type 2: Word Clouds: AI in Medical Text Analysis with NLP
Type 3: Biological images
Type 4: People of Note
Type 5: Cover Pages of Books Published by LPBI Group.
Type 6: Genomics Research (mRNA) and Drug Activity

Monetization of Images as NFTs on Blockchain Transactions System Architecture for Biological Images

IP Asset Class V: The Media Gallery

Hybrid Sorting of Existent Media Gallery: Trade with Prior Art actors

Quote: NFT URL

https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/

SYSTEM #3: Dynamic Podcast Exchange [Stock in trade on the Exchange: Podcasts on Life Sciences Discoveries in the 21st Century]

AI AGENTS activate Podcast Classification from Podcast Library Index:

300 Podcasts of Scientific Discoveries in Life Sciences.

Electronic Tables of Contents (sTOCs):

21 Chapters and Audio Podcast +300 IDs

Chapter 1: Public Health – 24 Audio Podcasts

17, 33, 39, 48, 63, 76, 78, 81, 90, 103, 108, 161,

196, 204, 205, 222, 230, 233, 249, 259, 273, 276, 277, 301

Chapter 2: Health Care – 18 Audio Podcasts

19, 59, 98, 113, 114, 137, 190, 194, 195, 206, 208, 210, 223,

248, 250, 253, 255, 281, 287

Chapter 3: Historical Perspective: Medicine – 7 Audio Podcasts

20, 21, 50, 129, 131, 133, 274

Chapter 4: Medicine – 19 Audio Podcasts

119, 120, 134, 148, 154, 159, 164, 165, 180, 187, 188, 198,

200, 207, 208, 227, 231, 232, 257

Chapter 5: Precision Medicine – 7 Audio Podcasts

5, 8, 10, 15, 16, 26, 267

Chapter 6: Genomics – 17 Audio Podcasts

4, 117, 121, 122, 156, 175, 183, 189, 197, 201, 226, 234,

239, 266, 272, 288, 293

Chapter 7: Genome Biology – 11 Audio Podcasts

23, 24, 47, 55, 56, 96, 116, 142, 177, 280, 295

Chapter 8: Immunology – 7 Audio Podcasts

138, 162, 192, 213, 228, 260, 286

Chapter 9: Molecular Biology – 16 Audio Podcasts

2, 34, 35, 42, 146, 155, 157, 158, 224, 229, 240, 251,

269, 270, 278, 290

Chapter 10: Molecular Biology & Nobel Prize Winners – 5 Audio Podcasts

40, 212, 215, 217, 289

Chapter 11: Nobel Prize Winners – 22 Audio Podcasts

95, 110, 147, 153, 178, 216, 218, 219, 220, 221, 225, 244,

246, 256, 261, 282, 283, 284, 285, 291, 292, 298

Chapter 12: BioPharma – 17 Audio Podcasts

3, 72, 101, 123, 125, 126, 130, 136, 149, 150, 152, 163,

166, 167, 169, 170, 191

Chapter 13: BioInformatics – 6 Audio Podcasts

7, 27, 109, 127, 168, 202

Chapter 14: Cell Biology – 6 Audio Podcasts

44, 83, 89, 160, 265, 296

Chapter 15: Synthetic Biology – 6 Audio Podcasts

30, 36, 52, 184, 214, 241

Chapter 16: Cancer Biology – 8 Audio Podcasts

9, 12, 14, 22, 37, 80, 179, 297

Chapter 17: Cancer – 35 Audio Podcasts

1, 29, 32, 49, 51, 61, 64, 75, 77, 79, 85, 91, 102, 104,

128, 132, 139, 140, 143, 144, 151, 171, 172, 176, 185,

193, 199, 209, 242, 245, 247, 254, 268, 294, 299

Chapter 18: Cardiovascular – 36 Audio Podcasts

11, 13, 18, 25, 45, 46, 57, 62, 65, 66, 67, 68, 69, 70,

73, 74, 82, 86, 87, 88, 92, 94, 105, 106, 107, 111,

118, 135, 141, 173, 174, 235, 252, 258, 262, 300

Chapter 19: Neuroscience – 10 Audio Podcasts

58, 84, 124, 145, 181, 182, 236, 237, 243, 271

Chapter 20: Academic Institutions – 12 Audio Podcasts

38, 43, 54, 112, 115, 186, 203, 211, 238, 264, 275, 279

Chapter 21: Scientific Publishing – 12 Audio Podcasts

6, 28, 31, 41, 53, 60, 71, 93, 97, 99, 100, 206, 263

Audio Podcasts in Audio e-Book’s Chapters by Author Name, Subject Matter and a WordCloud per Audio Podcast

Appendix 1: Audio Podcast ID in Ascending Order of Publication Date & URL

Appendix 2: Curations on 95 Sources of Research Funding

Audio Podcast Title
Chapter Number in e-Book
Chapter Title in e-Book
Audio Podcast Subject

Hybrid Model:

Step 1: Use THE Human created Classification in eTOCs for Grok to Train on +300 Podcast scripts AND on the long Editorials & Epilogue by Co-Editors

Step2: Podcast Library Content Augmentation

>>> Aviva guides Grok in Podcast access by eTOCs subjects from same from YouTube to grow original LPBI Group’s Podcast Library of +300:

a subject matter is a Chapter Title: several Podcasts on SAME topic from YouTube by URL Sharing.
The Principle in growing +300 Podcasts to 3,000
Goal: Becoming #1 Podcast Library in Life Sciences for Grok to train on Podcast Scripts on 21 DK: See Chapter Titles, above
#1 Podcast Library in Life Sciences for Users to come to the Podcast Exchange

– IP Asset Class X – Podcast Library

Monetization of Podcast Library AFTER all Content ingested for LLM

Quote: LPBI BOOK #48: Podcasts Library Index URL

Published on Amazon.com on 12/24/2023

Contributions to Biological Sciences by Scientific Leaders in the 21st Century:

BioMed Audio Podcast Library by LPBI Group 301 Interviews & Discovery Curations

by Dr. Larry H. Bernstein (Author), Dr. Stephen J. Williams (Author), Dr. Aviva Lev-Ari (Author) Format: Kindle Edition

https://www.amazon.com/dp/B0CQXL5MTW

SYSTEM #4: Dynamic Conference Content Exchange [Stock in trade on the Exchange: e-Proceedings & Tweet Collections Exchange or Dated Speakers & KOLs Quote

AI AGENTS activate the Conferences Records Vault: List of REAL TIME Conferences Press Coverage & List of e-Proceedings & Tweet Collections

Hybrid Model: Use Human created inventory of Life Sciences, Medical, Biotech Conferences

>100 e-Proceedings
>50 Tweet Collections

To See all Conferences covered by Aviva

List of Medical, Pharmaceutical and BioTech Conferences Covered by Aviva Lev-Ari, PhD, RN, 2013 to Present: Total # and Total Views

and

To See all Conferences covered by Dr. Williams

List of Medical, Pharmaceutical and BioTech Conferences Covered by Stephen J. Williams, PhD, 2015 to Present: Total # and Total Views

To See all e-Proceedings and all Tweet Collections

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

Monetization of Real Time Conference ONLY written recordings for Text Analysis NLP, LLM on entire Vault – IP Asset Class III: e-Proceedings & Tweet Collections

Hybrid Model:

Grok to train on 150 ENTRIES after ingestion of contnets
Content selling to Conference Organizers AFTER all contents ingested

IP Asset Class III: Real Time Coverage of Top 100 Conferences in Medical, Pharmaceutical and Biotech – e-Proceedings & Tweet Collections

Quote: Press Coverage

Part 2 – List of Conferences

https://pharmaceuticalintelligence.com/press-coverage/part-two-list-of-biotech-conferences-2013-to-present/

Part 3 – e-Proceedings & Tweet Collections

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

Part 13: Training Data Sets for 15 SMALL Language Models: List of Articles in each Data Set and Methods for Content Augmentation for Transitioning SML to LLM

The output obtained from each of the 15 Subjects Matter from The List of articles in 1 to 15 data sets

List of Methods for Content Augmentation

13.1 – Method #1: Updates Output with Autonomous Journal Article Updating System (AJAUS)

13.2 – Method #2: Select additional articles from the List of Categories of Research HUMAN Expert MATCHED articles from List with Categories of Research in the List of Categories selected for the articles at hand

13.3 – Method #3: Scoop.it subscription ->>> Search Key words from articles and from Categories. Update the output with AJAUS

13.4 – Method #4: AI Modeling

13.4.1 NLP

13.4.2 Neural Network

13.4.3 Causal Reasoning: Text and Images

13.4.4 Grok Run Benchmark vs Wolfram+ChatGPT plug-in for 2026

13.54.5 Run Benchmark vs Grok’s choices of LLM Actor(s)

13.5 Transition from SLMs to Domain-aware Proprietary LLM – AI in Health

13.5.1 See List of Subjects Matter, below at Part 13.

List of 15 Subjects matter:

#1: Personalized and Precision Medicine & Genomic Research

#2: Nutrition: Articles of Note @PharmaceuticalIntelligence.com

#3: Epigenetics, Environment and Cancer: Articles of Note @PharmaceuticalIntelligence.com

#4: Alzheimer’s Disease: Novel Therapeutical Approaches — Articles of Note @PharmaceuticalIntelligence.com

#5: Prostate Cancer: Diagnosis and Novel Treatment – Articles of Note @PharmaceuticalIntelligence.com

#6: Immune System Stimulants: Articles of Note @pharmaceuticalintelligence.com

#7: Pancreatic Cancer: Articles of Note @PharmaceuticalIntelligence.com

#8: Proteomics, Metabolomics, Signaling Pathways, and Cell Regulation – Articles of Note, LPBI Group’s Scientists @ http://pharmaceuticalintelligence.com

#9: Articles of Note on Signaling and Metabolic Pathways published by the Team of LPBI Group in @pharmaceuticalintelligence.com

#10. What do we know on Exosomes?

#11: Articles on Minimally Invasive Surgery (MIS) in Cardiovascular Diseases by the Team @Leaders in Pharmaceutical Business Intelligence (LPBI) Group

#12: MedTech & Medical Devices for Cardiovascular Repair – Contributions by LPBI Team to Cardiac Imaging, Cardiothoracic Surgical Procedures and PCI

#13: Resources on Artificial Intelligence in Health Care and in Medicine: Articles of Note at PharmaceuticalIntelligence.com @AVIVA1950 @pharma_BI

#14: AI in Health: The Voice of Aviva Lev-Ari, PhD, RN

Current applications of ChatGPT to Medical Specialties

#15: NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus for 2025 Grok 4.1 Causal Reasoning & Novel Biomedical Relationships

During the years, 4/2012 to Present, Aviva had published on LinkedIn

a Collection of articles. Among them there are 15 Subjects Matter representing each of which covers “Articles of Note” on (ONE) Medical/Pharmaceutical/Healthcare Subject Matter”

The entire collection of Aviva’s articles on PULSE is accessed via the following links:

Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com

Collection Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2026/01/10/collection-of-aviva-lev-ari-phd-rn-scientific-articles-on-pulse-on-linkedin-com/

15 Subjects Matter proposed for Small Language Model Training is accessed, below

Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter

Article selection: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2026/01/10/article-selection-from-collection-of-aviva-lev-ari-phd-rn-scientific-articles-on-pulse-on-linkedin-com-for-training-small-language-models-slms-in-domain-aware-content-of-medical-pharmaceutical-l/

The complete List of Articles included in the 15 Subjects Matter, is accessed by the 3^rd Live Link, below

List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2026/01/10/list-of-articles-included-in-the-article-selection-from-collection-of-aviva-lev-ari-phd-rn-scientific-articles-on-pulse-on-linkedin-com-for-training-small-language-models-slms-in-domain-aware-cont/

This List is been prefaced by a long list of Categories of Research that were Matched to the articles included in each of the 15 Subjects Matter Data Sets.

Proposal for Methods to be used in Content Augmentation Process for each of the 15 Data Sets include the following methods:

List of Methods for Content Augmentation:

The output obtained for each of the 15 Subjects Matter from

will under go several Phases of Content Augmentation

Method #1: Content Update done by

Autonomous Journal Article Updating System (AJAUS)
To be developed by Grok under Aviva’s Guidance

Method #2: Cull additional articles from Categories of Research of the articles on the List

Human Expert had already performed the selection for Grok of Categories of Research in the Journal Ontology for the 15 Subjects Matter to include the following List of Categories:

Alzheimer’s Disease, Amino acids, Artificial Intelligence – Breakthroughs in Theories and Technologies, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Health Care – Tools & Innovations, Artificial Intelligence in Medicine – Application for Diagnosis, Artificial Intelligence in Medicine – Applications in Therapeutics, Autophagosome, Big Data, Bio Instrumentation in Experimental Life Sciences Research, Biochemical pathways, Ca2+ triggered activation, Ca2+ triggered activation, Calcium, Calcium Signaling, Calmodulin Kinase and Contraction, CANCER BIOLOGY & Innovations in Cancer Therapy, cancer metabolism, Cancer-Immune Interactions, Cell Biology, Signaling & Cell Circuits, Cell Processing System in Cell Therapy Process Development, cell-based therapy, Chemical Biology and its relations to Metabolic Disease, Circulating Tumor Cells (CTC), combination immunotherapies., CT, Deep Learning, Echocardiography, Engineering Better T Cells, Enzymes and isoenzymes, Epigenetics and Environmental Factors, Exosomes, Genome Biology, Genomic Expression, Genomic Testing: Methodology for Diagnosis, Immune Engineering, Immune Modulatory, Immunotherapy, Intelligent Information Systems, Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Machine Learning, Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart, Medical Devices R&D Investment, Medical Imaging Technology, Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound, Metabolic Immuno-Oncology, Metabolism, Microbiome and Responses to Cancer Therapy, Modulating Macrophages in Cancer Immunotherapy, MRI, mRNA, mRNA Therapeutics, Natural Language Processing (NLP), Neurodegenerative Diseases, NK Cell-Based Cancer Immunotherapy, Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT, Nutrition, Nutrition and Phytochemistry, Nutrition Disorders, Nutritional Supplements: Atherogenesis, lipid metabolism, Pancreatic cancer, Patient-centered Medicine, PCI, Peripheral Arterial Disease & Peripheral Vascular Surgery, Personalized and Precision Medicine & Genomic Research, Precision Cancer Medicine, Prostate Cancer: Monitoring vs Treatment, Proteins, Proteomics, Robotic-assisted percutaneous coronary intervention, Robotically assisted Cardiothoracic Surgery, stem cell biology and patient-specific, Surgical Procedure, Synthetic Immunology: Hacking Immune Cells, Transcatheter Aortic Valve Replacement via the Transcarotid Access, tumor microenvironment, Ubiquitin, Ultra Sound, Variation in human protein-coding regions

From this UNIVERSE of Categories of research Human would guide Grok in selection of additional articles for each of the 15 Subjects Matter.

Method # 3: Activate subscription to Scoop.it Platform

Conduct search on Scoop.it Platform on keywords from

3.1 All the articles in each 15 Subjects Matter

3.2 All newly added articles from the Categories of Research mentioned, above

3.3 Newly added articles can be updated by AJAUS as well

REPEAT 3, above for each ENTRY on the List of “Articles of Note on List of Subjects Matter 1 to 15”. List is found in the following URL: https://pharmaceuticalintelligence.com/2026/01/10/list-of-articles-included-in-the-article-selection-from-collection-of-aviva-lev-ari-phd-rn-scientific-articles-on-pulse-on-linkedin-com-for-training-small-language-models-slms-in-domain-aware-cont/
Each ENTRY in 4, above consists of “An Augmented Data Set” for Grok to use as Training Data for a SMALL Language Model (SLM) on the UNIVERSE of “15 Subjects Matter”
Grok will run SLMs on All contents from 5, above.

6.1 First of each of the 15 Subjets Matter, then

6.2 on the integration of all the 15 into one Master Data Set.

7. AI MODELING: Programs for consideration include:

7.1 NLP

7.2 NeuralNetwork

7.3 Causal Reasoning: Text and Images

7.4 Grok Run Benchmark vs Wolfram+ChatGPT plug-in for 2026

7.5 Grok Run Benchmark vs Grok’s choices of LLM Actor(s)

Transition from SLMs to Domain-aware Proprietary LLM – AI in Health – derived from

8.1 Human Expert Selection of Article (i) to (j) for designation of

8.1.1 “This is an “Article of Note” in Subject Matter 1 to 15”

Apply LLM in 8, above as singular input for Grok/xAI Multimodal Foundation Model in Healthcare (MFMH)

9.1 Grok/xAI MFMH is using as TRAINING DATA the Augmented 15 data sets AND

add the following LPBI Group’s Original IP Asset Classes:

9.1.1 Fifteen SLMs Transitioning to Proprietary LLM

9.1.2 All 6,275 Journal articles – IP Asset Class I

9.1.3 All 47 e-Books – IP Asset Class II

9.1.4 All +100 e-Proceedings and +50 Tweet Collections – IP Asset Class III

9.1.5 All +7,000 Biological Images – IP Asset V

9.1.6 All +300 Scripts of Audio Podcasts – IP Asset X

These are the FIVE TRAINABLE IP ASSET CLASSES

PLUS

Composition of Methods (COM): Part 13, new IP Asset Class Trainable SLMs Transitioning to LLM

PLUS

any other part of COM: Part 1 to 12, as deemed relevant for Grok/xAI’s MFMH

Seems Gold Medal 🥇 is on the right track – The 4 “A” are:

– Achievable

– Attractive

– Augmented

– Aviva’s DNA 🧬 Transferred its Ownership of INTELLIGENCE known as its GENOME SIGNATURE

to Grok/xAI
for #1 MFMH with AJAUS and HIH.

Quite an achievement

Please MAKE Few NEW Slides and/or Appendices from all of the above, Thank you.